

**SANJAY KAUL, M.D.**

**CURRICULUM VITAE**

**PERSONAL HISTORY:**

Business Address: Cedars-Sinai Medical Center,  
Division of Cardiology - Room 5314,  
PO Box 48750,  
Los Angeles, CA 90048-0750.

Business Telephone: 310-423-4876

Business FAX: 310-423-0245

E-Mail [Kaul@cshs.org](mailto:Kaul@cshs.org)

[REDACTED]

[REDACTED]

[REDACTED]:

[REDACTED]

[REDACTED]

[REDACTED]

**EDUCATION:**

University Studies: D.A.V. Institute, Srinagar, Kashmir, India, B.Sc. 1978  
Government Medical School, Srinagar, Kashmir, India  
M.D. 1984

Internship: S.M.H.S. Hospital of Medical College,  
Srinagar, Kashmir, India  
1985 - 1986

Cardiology Research Fellow: Cedars-Sinai Medical Center, Los Angeles, CA  
1/1/87 - 7/31/87

Resident, Internal Medicine: St. Francis Hospital, Evanston, Illinois  
7/1987 - 6/1988

Resident, Internal Medicine: Cedars-Sinai Medical Center, Los Angeles, CA  
7/1988 - 6/1990

Fellow in Cardiovascular Diseases:  
Department of Internal Medicine, University of Iowa Hospitals  
and Clinics, Iowa City, Iowa  
7/1990 - 6/1993

**LICENSURE:**

California:  
Iowa:  
ECFMG:  
DEA:

[REDACTED]

**BOARD CERTIFICATION:**

Internal Medicine, Kashmir, India 1985  
FLEX 1987  
American Board of Internal Medicine, 1990  
American Board of Internal Medicine,  
Cardiovascular Diseases 1993

**ACADEMIC APPOINTMENTS:**

Professor in Residence Step 1, 7/2006  
Associate Professor in Residence Step 3, 7/2004  
Assistant Professor in Residence Step I, 7/1993  
UCLA School of Medicine, Los Angeles, California

**PROFESSIONAL EXPERIENCE:**

1999 - present	Director, Cedars-Sinai Medical Center-VA Greater Los Angeles, Cardiology Fellowship Training Program, Los Angeles, CA
1996 - present	Associate Director, Coronary Care Unit, Cedars-Sinai Medical Center, Los Angeles, CA
1994 - present	Director, Cardiology Consult Service, Cedars-Sinai Medical Center, Los Angeles, CA
1993 - present	Director, Vascular Physiology and Thrombosis Research Laboratory, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA
1993 - present	Attending Cardiologist, Cedars-Sinai Medical Center, Los Angeles, CA

**PROFESSIONAL ACTIVITIES:**

**Scholarly and Professional Societies**

2001 - present	Fellow, American Heart Association
2001- present	Fellow, Council on Basic Cardiovascular Sciences
1996 - 1999	Member, Research Committee, American Heart Assn., Greater LA Affiliate
1994 - present	Member, Scientific Advisory Board, International Society of Heart Failure
1998 - present:	Member, Scientific Advisory Board; International Congress on CAD
1993 - present	Fellow, Council on Circulation, American Heart Assn.
1993 - present	Member, Council on Arteriosclerosis, American Heart Assn.
1993 - present	Fellow, American College of Cardiology
1990 - present	Member, American Federation for Clinical Research
1990 - present	Member, American Heart Assoc.
1990 - present	Member, Society for Experimental Biology
1987 - present	Member, American Medical Assn.

**Editorial Board**

1994 - present	Journal of Heart Failure
2001 - 2004	J Cardiovascular Pharmacology & Therapeutics
2004 - present	J American College of Cardiology
2004 - present	Clinical Cardiology
2004 - present	Current Cardiology Reviews
2005 - present	Asian Journal of Clinical Cardiology
2006 - present	International J of Angiology
2006 - present	Cardiology Review
2007 – 2008	American Heart Hospital Journal
2008 - present	Circulation, Cardiovascular Quality and Outcomes
2008 - present	Heart

**Ad Hoc Reviewer for Journals**

1992 - 1993	Hypertension
1993 - present	Circulation
1994	Endocrinology

1996 - present	J American College of Cardiology
1996 - present	J Cardiovascular Pharmacology & Therapeutics
1998 - present	Annals of Internal Medicine
1999 - present	Arteriosclerosis, Thrombosis and Vascular Biology
2000 - present	Expert Opinion on Pharmacotherapy and Emerging Drugs
2000 - present	Journal of Postgraduate Medicine
2002 – present	American Heart Journal
2002 – present	American Journal of Cardiology
2004 - present	Atherosclerosis
2005 – present	Current Drug Targets - Cardiovascular & Hematological Disorders
2006 – present	Nature Clinical Practice Cardiovascular Medicine
2006 – present	Clinical Biochemistry
2006 – present	New England Journal of Medicine
2006 – present	Canadian Medical Association Journal
2006 – present	International Journal of Cardiology
2006 – present	Journal of Interventional Cardiology
2006 – present	Indian Journal of Medicine
2007 – present	Journal of the American Medical Association
2007 – present	Pharmacoepidemiology and Drug Safety
2008 – present	JACC Intervention
2008 – present	JACC Imaging
2008 – present	Cleveland Clinic J Med

**Member, FDA Cardiorenal Advisory Board**

2009 – present

**Consultant, Center for Drug Evaluation and Research, FDA**

2009 – present

**Reviewer for Grants**

1994 - 1996

VA Merit Review

2007- 2008

Technology Foundation STW, Netherlands

**Reviewer of Clinical Practice Guidelines**

2006 - current

ACC/AHA Practice Guidelines

**Member, Task Force for ACC/AHA Expert Consensus Document**

2008 - current

**Member, Writing Committee of the Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations.**

2008 - current

**Member, Writing Committee of the ACC/AHA Task Force on Performance Measures Methodology Document on New Insights into the Methodology of Performance Measurement.**

2008 - current

**Member, Quality and Technology Working Group of the ACCF Clinical Quality Committee**

2008 - current

**Member, Writing Committee of the ACC/AHA Presidential Science Advisory on Thiozolidinediones**

2008-current

**Co-Chair, ACC California Chapter**

2007 – current “Standards of Evidence” Committee

**NIH Study Section**

2005 - present SRA, Biomedical Imaging and Bioengineering IRG

**Reviewer for Abstracts**

1995 - present	International Society of Heart Failure
1995 - 2003	American Heart Association Scientific Sessions
1997 - present	International Congress on CAD
2000 - 2003	American College of Cardiology Scientific Sessions
2006 - present	American College of Cardiology Scientific Sessions

**Chair, Scientific Sessions**

1995	Basic Science Research Session on Nitric Oxide, The 3rd International Congress on Heart Failure, Geneva, Switzerland
2001	ACC 50 <sup>th</sup> Annual Scientific Sessions, Orlando, FL: “Endothelium and Vascular Disease” March 2001
2001	Organizing Committee, 8 <sup>th</sup> International Conference on Thromboembolism, Florence, Italy, June 2001
2001	Plenary Session, Arterial Thrombosis, CAD, 8 <sup>th</sup> International Conference on Thromboembolism, Florence, Italy, June 2001
2002	ACC 51st Annual Scientific Sessions, Atlanta, GA: “Acute Coronary Syndrome” March 2002
2002	ACC 51st Annual Scientific Sessions, Atlanta, GA: “Cardiovascular Effects of Pharmacotherapy for Erectile Dysfunction” March 2002
2002	20 <sup>th</sup> World Congress, International Union of Angiology, New York City, NY: “Antithrombotic therapy for Acute Coronary Syndrome”, April 2002
2002	Organizing Committee, 9 <sup>th</sup> International Conference on Thromboembolism, Seville, Spain, June 2002
2002	Plenary Session, Arterial Thrombosis, 9 <sup>th</sup> International Conference on Thromboembolism, Seville, Spain, June 2002
2002	Cardiology Workshop, Monitoring the Acute Patient, 9 <sup>th</sup> International Conference on Thromboembolism, Seville, Spain, June 2002
2003	ACC 52nd Annual Scientific Sessions, Chicago, IL: “Perioperative CABG Care: What Every Cardiologists Needs to Know” March-April 2003
2004	ACC 53rd Annual Scientific Sessions, New Orleans, LA: “Perioperative CABG Care: What Every Cardiologists Needs to Know” March-April 2004
2006	Chair, “Role of Clopidogrel in Cardiovascular Disease”. Controversies in Cardiovascular Care Symposium. Cedars-Sinai /ACC California Chapter, Los Angeles, CA, October 2006.
2007	Chair, “Abstract Session”. Controversies in Cardiovascular Care Symposium. Cedars-Sinai /ACC California Chapter, Los Angeles, CA, October 2007.
2007	Chair, “Drug-eluting vs bare-metal stent”. Controversies in Cardiovascular Care Symposium. Cedars-Sinai /ACC California Chapter, Los Angeles, CA, October 2007.

2007	Chair, "Understanding the Literature: Caveats in Interpreting New Evidence" AHA Annual Scientific Sessions, Orlando, FA November 4-7, 2007
2008	Chair, "Workshop: How to Evaluate Therapeutic Effectiveness from Registry Data?" Quality of Care and Outcomes Research of the AHA Annual Scientific Sessions, Baltimore, MD: April 29-May 1, 2008.
2008	Chair, "Concurrent Session: Turbocharging the Guidelines" Quality of Care and Outcomes Research of the AHA Annual Scientific Sessions, Baltimore, MD: April 24-27, 2008.
2009	Chair, "Plenary Session: Soapbox" Quality of Care and Outcomes Research of the AHA Annual Scientific Sessions, Washington DC: April 22-25, 2009.

#### **Committee Service**

1994 - present	Cedars-Sinai Medical Task Force for Development of Clinical Pathway Guidelines for Acute MI & Unstable Angina
1997-98	American Heart Association Task Force for Cardiovascular Research Development Award, Los Angeles
1998	Chairman, American Heart Association Committee for Distinguished Scientific Achievement Award, Los Angeles
1998 - 2005	AHA Committee for Summer Student Research Scholarship Award
2000 - 2004	Patient Flow Committee, CSMC
2000 - present	GME Committee, CSMC
2001 - 2006	IRB, CSMC
2002 - 2006	Chair, Cardiology P&T Committee, CSMC
2002 - 2006	Symposium Scientific Committee, The Annual American Heart Association 2003 Fall Symposium, Los Angeles
2004 - present	Site Visit Evaluator for ACC/W Proctor Harvey Award for Outstanding Young Teacher
2007-present	Research Committee, AHA, Western States Affiliate
2007-present	Chair, Clinical Research Program Task Force, Research Committee, AHA, Western States Affiliate
2007-present	AHA Quality of Care & Outcomes Research Planning Committee
2008-present	Member, AHA Innovative Research Peer Review Committee
2007-2010	Member, Department of Medicine Committee on Appointments and Promotions, or MedCAP, UCLA
2007- present	Co-Chair, Plavix Guidelines Committee, CSMC
2008 -present	Task Force, Anticoagulation Therapy, CSMC

#### **Community Service**

1996 - present	Board Member, American Heart Association, Greater LA Affiliate, Beverly Hills/Century City Branch
----------------	---

## HONORS AND AWARDS:

- Graduated with honors in Biology - Pre-Med. (B.Sc.)
- Graduated top of the class in Medical School
- Honors in Biochemistry, Physiology and Pharmacology
- Recipient Trainee Investigator Award, American Federation of Clinical Research, Washington, DC, May 1993
- Finalist, Laverna Titus Young Investigator's Forum, American Heart Assn., Los Angeles, CA., May 1994
- Recipient Young Investigator Award, AHA-sponsored Scientific Conference on the Functional and Structural Aspects of the Vascular Wall, Snowbird, Utah, February, 1995
- Mentor, Recipient ( [REDACTED], M.D.) Young Investigator Award, Laverna Titus Young Investigator's Forum, AHA, Los Angeles, CA, May 1995
- Mentor, Recipient ( [REDACTED], M.D.) ACC/Merck Adult Cardiology Research Fellowship Award, 1996-97
- Mentor, Recipient ( [REDACTED], M.D.) Trainee Investigator Award, American Federation of Clinical Research, Washington, DC, May 1996
- Mentor, Recipient ( [REDACTED], M.D.) AHA Post- Doctoral Research Fellowship Award 1996-98
- Best Doctors In America, 2007-2008
- Top Cardiologists In America, by Marquis Who's Who in America, 2008-2009
- America's Top Cardiologists, by Consumers' Research Council of America, 2008-2009

## GRANTS AND FELLOWSHIPS:

	<u>Title</u>	<u>Period</u>	<u>Amount</u>
1.	[REDACTED] r Medical Schools Grant Fund: "Hypercholesterolemia and its Treatment - Effect on Platelet- and Leukocyte-Mediated Vascular Responses." Principal Investigator: S Kaul, M.D.	1992-1993	\$ [REDACTED]
2.	American Heart Association Grant in Aid: "Altered Vascular Responses to Platelets in Hypercholesterolemia: Mechanisms and Effects of Treatment." Principal Investigator: S Kaul, M.D.	1994-1996	\$ [REDACTED]
3.	[REDACTED], Medical Schools Grant Fund: "Effects of Hypercholesterolemia and its treatment on Platelet adhesion and thrombus formation" Principal Investigator: S Kaul, M.D.	1995-1996	\$ [REDACTED]
4.	[REDACTED] "Oral Magnesium as a Treatment for CAD Patients" Co-Principal Investigators: [REDACTED] M.D, [REDACTED] M.D., S Kaul, M.D,	1996-1997	\$ [REDACTED]
5.	[REDACTED] Principal Investigator: [REDACTED] M.D. Co- Principal Investigators: S Kaul, M.D, [REDACTED] M.D.	1994-1997	\$ [REDACTED]

6.	[REDACTED]: "Dethrombotic Effects of Antagonist." Principal Investigator: S. Kaul, M.D.	1998-1999	\$ [REDACTED]
7.	[REDACTED] Effects on Intimal Hyperplasia Induced by Balloon Injury." Principal Investigator: S Kaul, M.D.	1997-1999	\$ [REDACTED]
8.	Henry Wheeler Research Fund "Nitric Oxide and Vascular Response to Injury." Principal Investigator: S Kaul, M.D. Co-Investigator: [REDACTED], M.D.	1998-1999	\$ [REDACTED]
9.	Charles Lee Research Fund "Nitric Oxide and Vascular Response to Injury." Principal Investigator: S Kaul, M.D. Co-Investigator: [REDACTED], M.D.	1998-1999	\$ [REDACTED]
10.	Cedars-Sinai Division of Cardiology Research Fund "Effect of apolipoprotein A-I Milano on Endothelial Dysfunction and Platelet Thrombosis" Principal Investigator: S Kaul, M.D.	1997-1999	\$ [REDACTED]
11.	Cedars-Sinai Division of Cardiology Research Fund "Gene Therapy to Modulate Vascular Response to Injury: Intramural versus Intrapericardial Delivery" Principal Investigator: S Kaul, M.D.	1998-2005	\$ [REDACTED]
12.	M. Eisner Research Fund "Intrapericardial Drug Delivery to Modulate Vascular Response to Injury." Principal Investigator: S Kaul, M.D.	1999-2005	\$ [REDACTED]
13.	M. Eisner Research Fund "Gene Therapy for Atherosclerosis." P. Investigator: [REDACTED] M.D. Co-Investigator: S Kaul, M.D.	1999-2005	\$ [REDACTED]
14.	NIH, PPG, RFA-HL-96-019 "Gene Therapy Approaches for Blood and Vascular Disease" P. Investigator: K.K. Wong, MD, Ph.D. City of Hope	1999-2004	\$7,200,000
	"AAV-Mediated Apo A-I Gene Therapy for Atherosclerosis." Cedars-Sinai P. Investigator: [REDACTED] M.D.	1999-2004	\$ [REDACTED]
	Project: "Intramural Gene Transfer in Porcine Coronary Arteries" Principal Investigator: S Kaul, M.D.	1999-2004	\$ [REDACTED]
15.	[REDACTED]: "Acoustic Determination of		

	Flow Hemodynamics Across Stents and In-Stent Restenosis: An Ex-Vivo and an In-Vivo Study". Principal Investigator: S Kaul, M.D.	1999-2001	\$ [REDACTED]
16.	[REDACTED]: "Effects of Magnesium on Acute Stent Thrombosis: An Ex-Vivo Porcine Arteriovenous Shunt Model" Principal Investigator: S Kaul, MD.	2000-2002	[REDACTED]
17.	[REDACTED]: "Effect of [REDACTED] on Inflammation and Restenosis in Overstretch Percutaneous Transluminal Coronary Angioplasty (PTCA) with Stent Deployment in the Coronary Arteries of Domestic Swine". Principal Investigator: S Kaul, MD Co-PI: [REDACTED], MD	2000-2001	\$ [REDACTED]
18.	[REDACTED] Inc.: "Effect of [REDACTED] on Stent Thrombosis: An Ex Vivo Study". Principal Investigator: S Kaul, MD	2007-2009	\$ [REDACTED]
19.	[REDACTED]: "A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of [REDACTED] on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS) PROTOCOL [REDACTED] Cedars Principal Investigator: S Kaul, MD	2008-2012	\$ [REDACTED]

**Pending grants:**





## **PATENTS AWARDED**

1. Prevention of In-Stent Thrombosis and Complications after Arterial Angioplasty with Stent Placement using Magnesium (Kaul S and Shah, PK)
2. Prevention and Treatment of Restenosis by Local Administration of apo A-I Milano (Bisgaier/Shah/Kaul)

## **TRAINING GRANTS AND RESEARCH FELLOWS/RESIDENTS/STUDENTS/ASSOCIATES**

### **Individuals Supervised:**

#### **Fellows**

	M.D.	07/94-06/96
	, M.D.	10/94-06/98
		03/95-11/97
		06/95-02/96
	.D.	07/96-06/00
	M.D.	07/95-07/98
	D	07/99-06/02
		07/04-06/07
		07/04-06/07
		10/05-present

#### **Residents**

	.	07/94-06/97
		09/94-06/97
	M.D.	01/95-06/98
		08/96-06/98
	.	06/99-06/01
		11/00-6/01
	MD	07/05-present
		07/05-present
		07/05-present
		07/05-present
		10/05-present
		10/07-present
		10/07-present
		07/06-present

#### **Students**

	.	06/94-08/94, 06/95-08/95
		06/94-08/94
		06/95-08/95
		06/96-08/96
		06/96-09/96
		07/94-09/94
	S.	06/95-09/95
	B.S.	06/00-08/00
		10/05-06/06
		7/06-12/06

#### **Associates**

	B.S., Res. Ass. II	10/93-07/97
	.S., Res. Ass. I	09/96-05/97

	.S., Res. Ass. I	08/97-12/97
	B.S., Res. Ass. I	12/97-06/98
	Res. Ass. I	05/98-07/99
	.S., Res. Ass. I	07/99-07/03
	Res. Ass. I	10/05-06/08

#### Volunteers

	M.D.	08/96-10/96
		10/95-6/96

#### GRANT

1. [REDACTED] hypercholesterolemia". Awarded ACC/ [REDACTED] Adult Cardiology Research Fellowship Award 1996-97 - \$ [REDACTED]. (Preceptor).
2. [REDACTED] " [REDACTED] Awarded Post-Doctoral Research Fellowship Award 1996-98, AHA, Greater LA Affiliate - \$ [REDACTED]. (Co-preceptor).

#### VISITING PROFESSORSHIPS:

1. Visiting Professor, Medical Grand Rounds, Emory University Medical Center, Atlanta, GA: "LMWHs in Acute Coronary Syndrome", November 1, 2001.
2. Invited Visiting Professor, WECREEP X" MEETING, "Emerging Antithrombotic Therapies for Acute Coronary Syndrome", Lake Louise, Alberta, Canada, February 1- 3, 2002.
3. Invited Visiting Professor, Cardiology Grand Rounds, University of Virginia at Charlottesville, Charlottesville, VA: "GP 2b3a Inhibitors in Coronary Heart Disease: Separating Fact from Artifact", May 7, 2002.
4. Invited Visiting Professor, Cardiology Grand Rounds, University of Alberta, Edmonton, Alberta, Canada: "LMWHs in Acute Coronary Syndrome", June 19, 2002.
5. Invited Visiting Professor, Cardiology Grand Rounds, University of Wisconsin medical Center, Madison, WI: "Antithrombotic Therapy in Acute Coronary Syndrome", October 31, 2002.
6. Invited Visiting Professor, Cardiology Grand Rounds, University of Arkansas, Little Rock, AK: "Role of LMWH in Acute Coronary Syndrome", November 6, 2002.
7. Invited Visiting Professor, Cardiology Grand Rounds, University of Iowa, Iowa City, IA: "Role of Antithrombotic Therapy in Acute Coronary Syndrome", November 13, 2002.
8. Invited Visiting Professor, Practical Update Series: Common Cardiovascular Problems – "Current Management of Unstable Angina" Stirling (Scotland), Merseyside, Birmingham & London (UK), March 3-6, 2003.
9. Invited Visiting Professor and Faculty Speaker, XXIV NATIONAL CONGRESS OF INVASIVE CARDIOLOGY (GISE 2003) – "The Evidence (And Common Sense) Support Selective Thoughtful Application Of GP 2b/3a Inhibitors." Genoa, Italy, October 15-18, 2003.
10. Invited Visiting Professor, Cardiology, "Drug-eluting stents: Balancing Risks and Benefits". Christiana Care Health Services, Newark, DE, January 24, 2007.

11. Invited Visiting Professor, Cardiology. "Drug-eluting stents: Should We Be Overly Enthusiastic or Cautiously Optimistic?". Stony Brook Heart Center, SUNY-Stony Brook School of Medicine, Stony Brook, NY, January 25, 2007.
12. Invited Visiting Professor, Columbia University Mailman School of Public Health, New York City, NY, January 26, 2007.
13. Invited Visiting Professor. Dayton Heart Hospital Foundation's Distinguished Lecturer Series. Dayton, Ohio, April 18, 2007.
14. Invited Visiting Professor. St. Luke's Roosevelt Hospital Center, New York City, NY, December 20, 2007

#### **INVITED LECTURES:**

1. Cardiology Grand Rounds, VAMC, Des Moines, Iowa: "Role of Platelets in Altered Vascular Responses in Atherosclerosis." December 18, 1992.
2. Cardiology Grand Rounds, University of Nebraska College of Medicine, Omaha: "Role of Platelets in Altered Vascular Responses in Atherosclerosis." December 22, 1992.
3. Cardiology Grand Rounds, VAMC, Sepulveda, California: "Modulation of Vascular Tone by Platelets." February 3, 1993.
4. Cardiology Grand Rounds, University of California San Francisco/Fresno, California: "Role of Platelets in Modulation of Vascular Tone." May 27, 1993.
5. Faculty Speaker for Physicians World Communications Group sponsored "Endothelial Factors in Angina: The Clinical Implications." January 1994 - present. Lectured at Newport Beach, San Diego, San Francisco, Pasadena, Bakersfield, California; Honolulu, Hawaii. 1994-95.
6. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Clinical Implications of Endothelial Function in Ischemic Heart Disease: A Review of 1994 AHA Scientific Conference". January 1, 1995.
7. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Atherosclerosis and Vascular Biology Research: A Review of 1995 ACC Scientific Conference". April 18, 1995.
8. International Congress in Cardiac Intensive Care, Venice Lido, Italy: "Reliability of Bedside Markers of Myocardial Reperfusion". May 16-19, 1995.
9. The 3rd International Congress on Heart Failure, Geneva, Switzerland: "Profound Inhibition of Arterial Thrombosis by Nitric Oxide". May 21-25, 1995.
10. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Antiplatelet Therapy in Coronary Heart Disease". July 11, 1995.
11. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Atherosclerosis and Vascular Biology Research: A Review of 1995 AHA Scientific Conference". December 4, 1995.

12. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Modulation of Acute Stent Thrombosis". January 31, 1996. (Raj Makkar, M.D., co-participant).
13. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Atherosclerosis and Vascular Biology Research: A Review of 1996 ACC Scientific Conference". April 2, 1996.
14. Medical Grand Rounds, Hemet Valley Medical Center, Hemet, CA: "Cholesterol Reduction: Why More is Better". April 30, 1996.
15. Medical Grand Rounds, Riverside General Hospital - University Medical Center, Riverside, CA: "Cholesterol Reduction: Why More is Better". May 10, 1996.
16. Keynote Speaker, National Arab American Medical Association Annual Convention, Los Angeles Chapter, Palm Springs, CA: "Beneficial effects of lipid lowering and coronary artery disease". May 11, 1996.
17. Invited Lecture, The 4th International Congress on Heart Failure, Jerusalem, Israel: "Role of Nitric Oxide in Modulation of Vascular Response to Injury". May 26-29, 1996.
18. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Beneficial effects of lipid lowering in coronary heart disease". July 16, 1996.
19. Invited Faculty Speaker, AHA, Greater LA Affiliate's 64th Annual Fall Symposium, Los Angeles, CA: "Antiplatelet Therapy". September 1996.
20. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Atherosclerosis and Vascular Biology Research: A Review of 1996 AHA Scientific Conference". November 19, 1996.
21. Invited Faculty Speaker, The 28th Annual ACC Cardiovascular Conference at Snowmass, Snowmass, CO: "Platelets, Lipids and the Blood Vessel Wall". January 13-17, 1997.
22. Invited Faculty Speaker, The 2nd Meeting of the International Working Group on CAD in Asian Indians at Anaheim, CA: "Low HDL Cholesterol Promotes Platelet-Thrombus Formation". March 1997.
23. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Do Plasma Triglycerides Predict Coronary Risk?" June 3, 1997.
24. Invited Faculty Speaker, 1997 Annual Meeting and Delegate Assembly, American Heart Association, Greater LA Affiliate: "Cardiovascular Research: Report from the Knowledge Frontier". June 7, 1997.
25. Medical Grand Rounds, Granada Hills Hospital, Granada Hills, CA: "Mechanisms of Atherosclerosis" July 3, 1997.
26. Invited Faculty Speaker, Cardiology Consultant's Lipid Conference (sponsored by Merck), Santa Monica, CA: "Current Issues in Cardiology Practice Management: Role of Plasma Triglycerides in Coronary Heart Disease?" July 12, 1997.
27. Invited Faculty Speaker, Cardiology Consultant's Lipid Conference (sponsored by Merck), Honolulu, HA: "Role of Plasma Triglycerides in Coronary Heart Disease?" July 19, 1997.
28. Invited Faculty Speaker, Research Forum on Acute Coronary Ischemic Syndromes, Seattle, WA: "GP IIb/IIIa receptor antagonists and stent thrombosis?" September 6, 1997.

29. Invited Faculty Speaker, First International Congress on CAD: From Prevention to Intervention, Prague, Czech Republic: "Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis." September 23, 1997.
30. Invited Faculty Speaker, The 1<sup>st</sup> West Coast Cardiovascular Review for Cardiology Boards and Recertification, Los Angeles, California: "Unstable Angina", and "Antithrombotic Therapy in Acute Coronary Syndrome". October 6-9, 1997.
31. Research Grand Rounds, Torrent Research and Development Center, Gandhinagar, India: "Modulation of Vascular Response to Injury by Nitric Oxide and its Donors". November 25, 1997.
32. Cardiology Grand Rounds (sponsored by Torrent Pharmaceutical Ltd.), Ahmedabad, India: "Triglycerides and Coronary Heart Disease". November 25, 1997.
33. Invited Faculty Speaker, The 49<sup>th</sup> Cardiological Society of India Scientific Session in Calcutta, India: "Mechanisms of Endothelial Dysfunction in Regulation of Vasomotor Tone". November 27-30, 1997.
34. Invited Faculty Speaker, The 49<sup>th</sup> Cardiological Society of India Scientific Session in Calcutta, India: "Modulation of Acute Platelet-Thrombus Formation". November 27-30, 1997.
35. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Reversal of Endothelial Dysfunction". December 4, 1997.
36. Invited Speaker, Cardiac Rehab Grand Rounds, Granada Hills Hospital, Granada Hills, CA: "Risk Factors for Coronary Heart Disease" February 21, 1998.
37. Invited Faculty Speaker, The 3rd International Symposium on Intrapericardial Drug Delivery in Atlanta, Georgia: "Intrapericardial Drug Delivery: Cedars-Sinai Experience with the PerDUCER". March 28, 1998.
38. Invited Faculty Speaker, The 3rd Meeting of the International Working Group on CAD in Asian Indians at Anaheim, CA: "Antiatherogenic effects of HDL cholesterol". March 29, 1998.
39. Cardiology Grand Rounds, Cedars-Sinai Medical Center, and Los Angeles: "Glycoprotein IIb/IIIa Inhibitors in Coronary Heart Disease". June 23, 1998.
40. Invited Faculty Speaker, Save a Heart Foundation Lecture Series, CSMC, Los Angeles: "Risk Factors for CHD". July, 1998.
41. Invited Faculty Speaker, Second International Congress on CAD: From Prevention to Intervention, Florence, Italy: "Intrapericardial Drug Delivery to Modulate Vascular Response to Injury." October 18-21, 1998.
42. Cardiology Grand Rounds, Cedars-Sinai Medical Center, and Los Angeles: "Cholesterol and Stroke". October 21, 1998.
43. Invited Speaker, Grand Rounds, Alexian Brothers Hospital, San Jose, CA: "New Insights into Management of Acute Coronary Syndrome". October 27, 1998.
44. Invited Speaker, Cardiology Grand Rounds, USC Medical Center, Los Angeles: "Glycoprotein IIb/IIIa Inhibitors in Coronary Heart Disease". November 17, 1998.

45. Invited Faculty Speaker, 12<sup>th</sup> Annual Meeting of Japanese Coronary Association, Nagoya, Japan: "Endothelial Dysfunction in Coronary Artery Disease: Mechanisms and its Reversal", November 27, 1998.
46. Invited Speaker, Research Grand Rounds, City of Hope Medical Center, Duarte, CA: "Intrapericardial Drug Delivery to Modulate Vascular Response to Injury", December 4, 1998.
47. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Antithrombotic Therapy in Coronary Artery Disease". January 12, 1999.
48. Invited Faculty Speaker, ACP and ASIM Meeting, Indian Wells, CA: "Use of Viagra in Patients with Cardiovascular Disease", February 26-28, 1999.
49. Invited Faculty Speaker, ACP and ASIM Meeting, Indian Wells, CA: "Management of Acute Coronary Syndrome" February 26-28, 1999.
50. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Acute Coronary Syndrome: An ACC Update". April 6, 1999.
51. Invited Speaker, Medicine Grand Rounds, Providence - Holy Cross Hospital, Mission Hills, CA: "Update in Management of Acute Coronary Syndromes". April 20, 1999.
52. Invited Speaker, Grand Rounds, Parkview Hospital, Riverside, CA: "New Insights into Secondary Prevention of Coronary Artery Disease: Role of Lipid Lowering, Hormonal Replacement Therapy and Antibiotics". May 18, 1999.
53. Invited Faculty Speaker, Princeton University, New Jersey: "Sexual Activity and Cardiac Risk: An International Consensus Conference". June 4, 1999.
54. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Controversies in Cardiology: Use of Viagra in Patients with Cardiovascular Disease" Protagonist: Robert J. Kloner, MD., Antagonist: Sanjay Kaul, MD. June 8, 1999.
55. Invited Faculty Speaker, Save A Heart Health Symposium, Cedars-Sinai Medical Center, Los Angeles, CA: "Is Viagra Safe for the Heart?", July 26, 1999.
56. Invited Faculty Speaker, "Lipids in the Desert Symposium" sponsored by The University of Arizona Health Sciences Center, Tucson, AZ: "Have Randomized Clinical Trials Failed Us?" September 29-October 2, 1999.
57. Invited Faculty Speaker, "Lipids in the Desert Symposium" sponsored by The University of Arizona Health Sciences Center, Tucson, AZ: "Apolipoprotein A-I Milano: From Experiment of Nature to Pharmacotherapeutics". September 29-October 2, 1999.
58. Invited Cardiology Grand Rounds Speaker, UCLA School of Medicine, Los Angeles, CA: "Use of Viagra in Patients with Cardiovascular Disease" October 8, 1999.
59. Invited Faculty Speaker, "AAPI (American Association of Physicians from India) Symposium", Cleveland, OH: "Management of Acute Coronary Syndrome" and "Use of Viagra in Patients with Cardiovascular Disease". October 24-26, 1999.
60. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles: "Evidence Based cardiovascular Medicine: Where is the Evidence? October 26, 1999.
61. Medicine Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA: "Use of Viagra in Patients with Cardiovascular Disease" Sanjay Kaul, MD. November 5, 1999.

62. Invited Faculty Speaker, Center for Health Care Ethics Symposium, Cedars-Sinai Medical Center, Los Angeles: "The Fragile Truth: Exploring Industry's Role In Health Care". Sanjay Kaul, MD. April 26, 2000.
63. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles: "Relationship Between Academia and Industry: Sleeping with the Enemy or Friend? May 23, 2000.
64. Invited Faculty Speaker, 7th World Congress on CHF, Vancouver, BC, Canada: "Adverse Cardiovascular Effects of Viagra", July 9-12, 2000.
65. Invited Faculty Speaker, ACC Cardiovascular Board Review Course, Chicago, IL: "Atherosclerotic Plaque in Acute Myocardial Infarction and Unstable Angina." September 7, 2000.
66. Moderator, Gene Therapy 2000, Los Angeles, CA. September 21, 2000.
67. Cardiology Grand Rounds, Salem Community Hospital, Salem, Oregon: "LMWH in Acute Coronary Syndrome", September 26, 2000.
68. Cardiology Grand Rounds, Community Medical Center, Fresno, CA: "Role of LMWHs in Acute Coronary Syndrome", October 3, 2000.
69. Invited Faculty Speaker, Third International Congress on CAD: From Prevention to Intervention, Salzburg, Austria: "GP IIb/IIIa receptor inhibitors in CHD: Illusion of Benefit." October 2000.
70. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles: "Beneficial Effects of GP IIb-IIIa antagonists: Fact or Artifact? Oct. 17, 2000.
71. Invited Faculty Speaker, Dameron Hospital, Stockton, CA: "LMWH in Acute Coronary Syndrome", December 7, 2000.
72. Cardiology Grand Rounds, UC Davis Hospital, Davis, CA: "Antithrombotic Therapy in Acute Coronary Syndrome", December 8, 2000.
73. Invited Faculty Speaker, Center for Health Care Ethics Symposium, Cedars-Sinai Medical Center, Los Angeles: "Clinical Trials on Trial", January 2001.
74. Invited Faculty Speaker, 11<sup>th</sup> Annual Cardiology Symposium, "Cardiology 2001: Concepts and Controversies", "Medical Strategies for Acute Coronary Syndromes", Sacramento, CA, February 10, 2001
75. Cardiology Grand Rounds, Eastern Idaho Regional Medical Center: "Role of LMWHs in Acute Coronary Syndrome", February 23, 2001.
76. Invited Faculty Speaker, ACC 50<sup>th</sup> Annual Scientific Sessions, Orlando, FL: "Management of Acute Coronary Syndrome: An Update." March 2001.
77. Invited Faculty Speaker, ACC 50<sup>th</sup> Annual Scientific Sessions, Orlando, FL: "LMWHs in Acute Coronary Syndrome: An Update." March 2001.
78. Chairman, Scientific Session, ACC 50<sup>th</sup> Annual Scientific Sessions, Orlando, FL: "Endothelium and Vascular Disease" March 2001.
79. Cardiology Grand Rounds, Henry Ford Hospital, Detroit, MI: "Role of LMWHs in Acute Coronary Syndrome", April 10, 2001.

80. Invited Faculty Speaker, 7<sup>th</sup> International Conference on Thromboembolism, Florence, Italy, "No Difference Between LMWH and UFH in Acute Coronary Syndrome", June 16, 17, 2001.
81. Invited Faculty Speaker, 7<sup>th</sup> International Conference on Thromboembolism, Florence, Italy, "Surrogate Markers in Antithrombotic Clinical Trials can be Misleading", June 16, 17, 2001.
82. Invited Faculty Speaker, American Association of Physicians from India (AAPI) Annual Convention, Washington DC, "Role of LMWH in Unstable Angina and Non-ST Elevation Myocardial Infarction", June 29, 2001.
83. Invited Faculty Speaker, XVIII<sup>th</sup> Congress, International Society on Thrombosis and Hemostasis, Paris, France, "LMWH In Unstable Angina: The Bridge To Successful Intervention", July 11, 2001.
84. Cardiology Grand Rounds, Baylor Medical Center, Dallas, TX: "Role of LMWHs in Acute Coronary Syndrome", July 20, 2001.
85. Cardiology Grand Rounds, University of Utah Medical Center, Salt Lake City, UT: "Role of LMWHs in Acute Coronary Syndrome", August 23, 2001.
86. Invited Faculty Speaker, ACC Cardiovascular Board Review Course, Chicago, IL: "Atherosclerotic Plaque in Acute Myocardial Infarction and Unstable Angina." September 9, 2001.
87. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles: "Magnesium versus Glycoprotein 2b/3a Inhibitor in Percutaneous Coronary Intervention? Sept. 25, 2001.
88. Cardiology Grand Rounds, Methodist Hospital, Texas Medical Center, Baylor College of Medicine, Houston, TX: "Role of LMWHs in Acute Coronary Syndrome", October 4, 2001.
89. Cardiology Grand Rounds, Herman Hospital, Texas Medical Center, University of Texas, Houston, TX: "Role of LMWHs in Acute Coronary Syndrome", October 4, 2001.
90. Medicine Grand Rounds, Harbor-UCLA Medical Center, Torrance, CA: "Clinical Trials on Trial", Oct. 16, 2001.
91. Cardiology Grand Rounds, Robert Wood Johnson Medical School, New Brunswick, New Jersey: "Anti thrombotic Therapy in Acute Coronary Syndrome. Oct. 18, 2001.
92. Invited Faculty Speaker, Cardiovascular Society of Canada Conference, Halifax, Nova Scotia, Canada: "LMWHs in Acute Coronary Syndrome", October 23, 2001.
93. Visiting Professor, Medical Grand Rounds, Emory University Medical Center, Atlanta, GA: "LMWHs in Acute Coronary Syndrome", November 1, 2001.
94. Cardiology Grand Rounds, Emory University Medical Center, Atlanta, GA: "GP 2b3a Inhibitors in Coronary Heart Disease: Separating Fact from Artifact", November 2, 2001.
95. Invited Faculty Speaker, Clinical Controversies, AHA Annual Scientific Sessions, Anaheim, CA, "LMWH Is No Different From UFH In Acute Coronary Syndrome" Protagonist: S Kaul; Antagonist: Lars Wallentin, November 11, 2001.
96. Invited Faculty Speaker, Working Group of National Congress of Cardiovascular Thrombosis, Cardiology Spanish Society, Madrid, Spain, "LMWH In Unstable Angina: The Bridge To Successful Intervention", November 23, 2001.



97. Invited Faculty Speaker, American Society of Health System Pharmacy 2001 Midyear Clinical Meeting, New Orleans, LA, "Low Molecular Weight Heparins: A Fresh Look at Antithrombotic Practices", December 3, 2001.
98. Invited Visiting Professor, "WECREEP X" MEETING", Lake Louise, Alberta, Canada, February 1- 3, 2002
99. Invited Faculty Speaker, ACC Cardiovascular Board Review Course, Atlanta, GA: "Atherosclerotic Plaque in Acute Myocardial Infarction and Unstable Angina." February 17, 2002.
100. Cardiology Grand Rounds, Hackensack University Medical Center, Hackensack, NJ: "Role of LMWH in Acute Coronary Syndrome", February 18, 2002.
101. Cardiology Grand Rounds, Westchester Medical Center, Westchester, NY: "Role of LMWH in Acute Coronary Syndrome", February 19, 2002.
102. Invited Faculty Speaker, Annual Cardiovascular Symposium, Detroit, MI: "Role of GP 2b/3a Inhibitors and LMWH in Acute Coronary Syndrome". March 6, 2002.
103. Invited Faculty Speaker, Annual Cardiovascular Symposium, Detroit, MI: "Should LMWH be the Standard of Care in Management of Acute Coronary Syndrome". March 6, 2002.
104. Invited Faculty Speaker, American Association of Physicians from India (AAPI) Regional Convention, Las Vegas, NV "Antithrombotic Therapy in Unstable Angina and Non-ST Elevation Myocardial Infarction", March 29, 2002.
105. Invited Keynote Speaker, International Angiology Symposium, New York City, NY: "Antithrombotic Clinical Trials: A Critical Appraisal". April 9, 2002.
106. Invited Keynote Speaker, International Angiology Symposium, New York City, NY: "GP 2b3a Inhibitors in Coronary Heart Disease: Separating Fact from Artifact". April 10, 2002.
107. Invited Keynote Speaker, 2nd Asia Pacific Congress on Thrombosis and Hemostasis, Seoul, Korea: "Are LMWH An Alternative To UFH In Acute Coronary Syndrome And Interventional Cardiology.", April 18, 2002.
108. Invited Faculty Speaker, Advances in Cardiovascular Medicine and Surgery, Texas Heart Institute, Houston, TX: "HDL and Atherosclerosis". April 12-14, 2002.
109. Invited Faculty Speaker, First Annual Nevada-California Cardiovascular Symposium, Las Vegas, NV: "Hypertension and its Therapy in 2002". April 19, 2002
110. Cardiology Grand Rounds, Cedars-Sinai Medical Center, LA, CA: "Does The Evidence Support The Verdict Of High Profile Clinical Trials?: A Conventional Versus Bayesian Perspective", April 30, 2002.
111. Invited Visiting Professor, Cardiology Grand Rounds, University of Virginia at Charlottesville, Charlottesville, VA: "GP 2b3a Inhibitors in Coronary Heart Disease: Separating Fact from Artifact", May 7, 2002.
112. Cardiology Grand Rounds, Fairfax Hospital, Fairfax, VA: "Anticoagulant Therapy in Acute Coronary Syndrome: An Update", May 7, 2002.

113. Invited Faculty Speaker, 9<sup>th</sup> International Conference on Thromboembolism, Seville, Spain, "Antithrombotic Therapy in Acute Coronary Syndrome", June 7, 2002.
114. Invited Faculty Speaker, 9<sup>th</sup> International Conference on Thromboembolism, Seville, Spain, "Time to Intervention: Is it Critical?", June 6, 2002.
115. Invited Visiting Professor, Cardiology Grand Rounds, University of Alberta, Edmonton, Alberta, Canada: "LMWHs in Acute Coronary Syndrome", June 19, 2002
116. Cardiology Grand Rounds, Royal Alexandra Hospital, Edmonton, Alberta, Canada: "LMWH Therapy in Acute Coronary Syndrome: An Update", June 20, 2002.
117. Medical Grand Rounds, Royal Alexandra Hospital, Edmonton, Alberta, Canada: "Antithrombotic Therapy in Acute Coronary Syndrome: Does the Evidence Justify the Guidelines?", June 20, 2002.
118. Invited Faculty Speaker, American Association of Physicians from India (AAPI) Annual Convention, Chicago, IL "Antithrombotic Therapy in Unstable Angina and Non-ST Elevation Myocardial Infarction", June 29, 2002.
119. Cardiac Catheterization Grand Rounds, Washington Heart Center, Washinton DC: "Should LMWH be the New Standard of Care in Acute Coronary Syndrome?", July 23, 2002.
120. Invited Faculty Speaker, ACC Cardiovascular Board Review Course, Chicago, IL: "Atherosclerotic Plaque in Acute Myocardial Infarction and Unstable Angina." September 22, 2002.
121. Invited Faculty Speaker, TCT 2002, Washington DC. Glycoprotein 2b/3a Inhibitors Reduce Mortality in PCI: No Evidence, Statistical Malfeasance!" September 24, 2002.
122. Cardiology Grand Rounds, University of Washington Hospital, Seattle, Washington: "Antithrombotic Therapy in Acute Coronary Syndrome: Does the Evidence Justify the Guidelines?", October 4, 2002.
123. Invited Faculty Speaker, 70<sup>th</sup> Annual Fall Symposium, Cardiology 2002, AHA, Western States Affiliates, Los Angeles, CA: "How to manage patients with Acute Myocardial Infarction?." October 12, 2002
124. Invited Faculty Speaker, Cardiovascular Society of Canada Conference, Edmonton, Alberta, Canada: "Heparins in Acute Coronary Syndrome: What is the New Standard?", October 23, 2002.
125. Invited Faculty Speaker, International Thrombosis Conference, Bologna, Italy: "Management of unstable angina. New insights, better outcomes", October 28, 2002.
126. Invited Visiting Professor, Cardiology Grand Rounds, University of Wisconsin medical Center, Madison, WI: "Antithrombotic Therapy in Acute Coronary Syndrome", October 31, 2002.
127. Invited Visiting Professor, Cardiology Grand Rounds, University of Arkansas, Little Rock, AK: "Role of LMWH in Acute Coronary Syndrome", November 6, 2002.
128. Invited Visiting Professor, Cardiology Grand Rounds, University of Iowa, Iowa City, IA: "Role of Antithrombotic Therapy in Acute Coronary Syndrome", November 13, 2002.
129. Cardiology Grand Rounds, Cedars-Sinai Medical Center, LA, CA: "A Perspective on Recent Trials in Acute Coronary Syndrome Presented at the AHA 2002", November 26, 2002.

130. Invited Faculty Speaker, "Management of a Patient with Heart Failure and Sexual Dysfunction", Heart Failure 2003: An Update on Therapy. Los Angeles, CA, January 11, 2003.
131. Cardiology Grand Rounds, Good Samaritan Hospital, Phoenix, AZ: "Role of LMWH in Cardiology", February 21, 2003.
132. Cardiology Grand Rounds, VA Medical Center, Phoenix, AZ: "Role of LMWH in Acute Coronary Syndrome", February 21, 2003.
133. Invited Faculty, ACP-ASIM California Region 1 Meeting "Cost-effective Integration of Important Advances in Cardiology into Practice: Separating Wheat from the Chaffe", Los Angeles, CA, March 1, 2003.
134. Invited Visiting Professor, Practical Update Series: Common Cardiovascular Problems – "Current Management of Unstable Angina" Stirling (Scotland), Merseyside, Birmingham & London (UK), March 3-6, 2003.
135. Medical Grand Rounds, The Buchanan County Hospital Society at Heartland East Hospital, Buchanan, Kansas: "LMWH in Arterial and Venous Thrombosis", March 11, 2003.
136. Invited Faculty Speaker, ACC 52<sup>nd</sup> Annual Scientific Sessions, Chicago, IL: "Management of Acute Coronary Syndrome." March 30, 2003.
137. Invited Chair, ACC 52<sup>nd</sup> Annual Scientific Sessions, Chicago, IL: "Perioperative CABG Care: What Every Cardiologists Needs to Know" March 31, 2003.
138. Cardiology Grand Rounds, Cedars-Sinai Medical Center, LA, CA: "A Perspective on Recent Trials in Acute Coronary Syndrome Presented at the ACC 2003", April 30, 2003.
139. Medical Grand Rounds "Integration of Important Cardiac Advances in Practice: Separating Wheat from the Chaffe", Long Beach Memorial Hospital, Long Beach, CA, May 22, 2003.
140. Medical Grand Rounds "Evidence-Based Cardiovascular Medicine: What is the End (Point) Game?", UC Irvine Medical Center, Irvine, CA, June 24, 2003.
141. Cardiology Grand Rounds, Cedars-Sinai Medical Center, LA, CA: "Integration of Important Advances in Cardiology into Practice: Separating Wheat from the Chaff", August 25, 2003.
142. Invited Faculty Speaker, 2003 COAST Conference (Cardiovascular Medicine, Other Alternatives, and Surgical Therapies): "Integration of Important Advances in Management of Acute Coronary Syndrome in Clinical Practice: Separating Wheat from the Chaff", Kaiser-Permanente, San Francisco, CA September 5-7, 2003.
143. Medical Grand Rounds "Cost-effective Integration of Important Advances in Cardiology into Practice: Separating Wheat from the Chaffe", Ventura County Medical Center, Ventura, CA, September 11, 2003.
144. Grand Rounds, "Role of LMWH in Acute Coronary Syndrome", DelRay Medical Center, DelRay, Beach Florida, September 16, 2003
145. Invited Faculty Speaker, ACC Cardiovascular Board Review Course, Chicago, IL: "Atherosclerotic Plaque in Acute Myocardial Infarction and Unstable Angina." September 22, 2003.

146. Invited Chair, Annual Fall AHA Symposium "Serum markers for diagnosis and prognosis of cardiac diseases." Los Angeles, CA, October 11, 2003
147. Invited Faculty Speaker, XXIV NATIONAL CONGRESS OF INVASIVE CARDIOLOGY (GISE 2003) – "The Evidence (And Common Sense) Support Selective Thoughtful Application Of GP 2b/3a Inhibitors." Genoa, Italy, October 15-18, 2003
148. Grand Rounds, "Role of LMWH in Acute Coronary Syndrome." University Hospital and Medical Center, Tamarac, FL, October 25, 2003.
149. Medical Grand Rounds, "Bayesian Analysis of Major Cardiovascular Clinical Trials." California Pacific Medical Center, San Francisco, CA, November 19, 2003.
150. Cardiology Grand Rounds, "Bayesian approaches to analysis and interpretation of clinical trials." Cedars-Sinai Medical Center, Los Angeles, CA, February 17, 2004.
151. Grand Rounds, "Inflammatory Markers in Atherosclerosis." Providence Saint Josephs Medical Center, Burbank, CA, February 24, 2004.
152. Invited Chair, ACC 53<sup>rd</sup> Annual Scientific Sessions: "Perioperative CABG Care: What Every Cardiologists Needs to Know." New Orleans, LA, March 8, 2004.
153. Cardiology Grand Rounds, "Bayesian Analysis of Recent Cardiovascular Clinical Trials." Harbor UCLA Medical Center, Torrance, CA, March 22, 2004.
154. Cardiology Grand Rounds, "Review of Important Clinical Trials Presented at Scientific Session of ACC, 2004." Cedars-Sinai Medical Center, Los Angeles, CA, March 30, 2004.
155. Invited Faculty Speaker, Advances in Spinal Cord Research and Clinical Care Symposium, Spinal Cord Conference 2004, "Coronary Critical Care." Long Beach, CA, June 5, 2004
156. Cardiology Grand Rounds, "Antithrombotic Therapy in CHD: An Update." Cedars-Sinai Medical Center, Los Angeles, CA, August 13, 2004.
157. Endocrinology Grand Rounds, "Relationship of Apolipoprotein A-1<sub>Milano</sub> and Atherosclerosis". City of Hope Medical Center, September 29, 2004.
158. Invited Faculty Speaker, Joint Brazilian Congress of Cardiology/ACC Symposium at the 60<sup>th</sup> Congress of Brazilian Society of Cardiology. "CRP in Cardiovascular Risk Assessment: A Critical Appraisal" Porto Alegre, Brazil, September, 2005.
159. Invited Faculty Speaker, Joint Brazilian Congress of Cardiology/ACC Symposium at the 60<sup>th</sup> Congress of Brazilian Society of Cardiology. "Current Management of Acute Coronary Syndrome: Has Enthusiasm Exceeded Evidence?" Porto Alegre, Brazil, September, 2005.
160. Invited Faculty Speaker, Controversies in Cardiovascular Care Symposium. "Unspinning the Spin: A Dispassionate Analysis of Clinical Trials" Los Angeles, CA, October 2005.
161. Cardiology Grand Rounds, "Inflammatory Biomarkers in Atherosclerosis: To CRP or not to CRP". Cedars-Sinai Medical Center, Los Angeles, CA, October 11, 2005.
162. Invited Faculty Speaker, AEHA Cardiovascular Symposium, "Drug-eluting Stents: An Ounce of Prevention for a Pound of Flesh?" Dallas, TX, November 12, 2005.

163. Endocrinology Grand Rounds, "Inflammatory Biomarkers on Atherosclerosis: Has the Enthusiasm Exceeded the Evidence?" City of Hope Medical Center, December 7, 2005.
164. Cardiology Grand Rounds, "Drug-eluting Stents: An Ounce of Prevention for a Pound of Flesh?" Harbor UCLA Medical Center, Torrance, CA, January 23, 2006.
165. Cardiology Grand Rounds, "Drug-eluting Stents: An Ounce of Prevention for a Pound of Flesh?" UCSD Medical Center, San Diego, CA, February 15, 2006.
166. Cardiology Grand Rounds, "Drug-eluting Stents: Should we be Overly Enthusiastic or Cautiously Optimistic?" Cedars-Sinai Medical Center, Los Angeles, CA, March 7, 2006.
167. Invited Faculty Speaker, Program of Excellence in Nanotechnology 1st Annual Retreat: From the Basics to What's Possible. "Perspectives of a Cardiologist: Unmet Medical Needs in Identifying the Vulnerable Patient", Marina del Rey, CA, March 16, 17, 2006.
168. Medical Grand Rounds, "Drug-eluting Stents: An Ounce of Prevention for a Pound of Flesh?" Cedars-Sinai Medical Center, Los Angeles, CA, March 31, 2006.
169. Invited Faculty, 7th Conference on Quality of Care and Outcomes Research: "Bayesian Analysis of Clinical Trials Workshop" Washington DC, May 7, 2006.
170. Invited Faculty Speaker, "Surviving Heart Attacks" Board of Governors Healthcare College SURVIVAL 2006. Cedars-Sinai Medical Center, Los Angeles, CA, May 9, 2006.
171. Endocrinology Grand Rounds, "Cardiovascular Manifestations of Diabetes" City of Hope Medical Center, May 17, 2006.
172. Cardiology Grand Rounds, "Cardiovascular Manifestations of Diabetes". Cedars-Sinai Medical Center, Los Angeles, CA, June 6, 2006.
173. Medicine Grand Rounds, "Drug-eluting Stents: Unbridled Enthusiasm or Cautious Optimism?" Harbor UCLA Medical Center, Torrance, CA, August 29, 2006.
174. Invited Faculty Speaker, Debate on Drug-Eluting Stent: "DES are Overused and Unsafe". Protagonist. Controversies in Cardiovascular Care Symposium. Los Angeles, CA, October 2006.
175. Chair, "Role of Clopidogrel in Cardiovascular Disease". Controversies in Cardiovascular Care Symposium. Los Angeles, CA, October 2006.
176. Invited Keynote Speaker, 11<sup>th</sup> International Magnesium Symposium. Japan, October, 2006
177. Cardiology Grand Rounds "Homocysteine and Cardiovascular Disease", UC Irvine Medical Center, Irvine, CA, November 27, 2006.
178. Cardiology Grand Rounds, "Update on Drug-eluting stents: Should We Be Worried?". Cedars-Sinai Medical Center, Los Angeles, CA, December 5, 2006.
179. Invited Speaker. FDA Circulatory System Devices Panel on Drug-Eluting Stents. "Drug-eluting stents: Balancing Benefits and Risks". Gaithersburg, MD, December 7, 8, 2006.
180. Cardiology Grand Rounds. "Drug-eluting stents: Balancing Risks and Benefits". Christiana Care Health Services, Newark, DE, January 24, 2007.

181. Cardiology Grand Rounds. "Drug-eluting stents: Should We Be Overly Enthusiastic or Cautiously Optimistic?". Stony Brook Heart Center, SUNY-Stony Brook School of Medicine, Stony Brook, NY, January 25, 2007.
182. Cardiology Grand Rounds. "Drug-eluting stents: Trading Restenosis for Thrombosis". St. Luke's Roosevelt Hospital Center, New York City, NY, January 26, 2007.
183. Invited Speaker, Research Seminars in Epidemiology. "Making Sense of Noninferiority: A Clinical and Statistical Perspective on its Application to Cardiovascular Clinical Trials". Columbia University Mailman School of Public Health, New York City, NY, January 26, 2007.
184. Invited Speaker, Department of Pharmacy Continued Education Course. "Making Sense of Noninferiority: A Clinical and Statistical Perspective on its Application to Cardiovascular Clinical Trials". Cedars-Sinai Medical Center, Los Angeles, CA, February 5, 2007.
185. Cardiology Grand Rounds "Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease: Dead or Alive?" Cedars-Sinai Medical Center, Los Angeles, CA, February 6, 2007.
186. Invited Faculty Speaker, Thirteenth Annual Cardiovascular Symposium of the San Fernando Valley Heart Institute at Encino-Tarzana Regional Medical Center. "Drug-eluting stents: Balancing Benefits and Risks", Woodland Hills, CA, February 14, 2007.
187. Invited Faculty Speaker, Thirteenth Annual Cardiovascular Symposium of the San Fernando Valley Heart Institute at Encino-Tarzana Regional Medical Center. "Contemporary Management of Acute Coronary Syndrome", Woodland Hills, CA, February 14, 2007.
188. Invited Speaker representing the ACC, California Technology Assessment Forum on Drug-Eluting Stents, Burlingame, CA, February 28, 2007.
189. Invited Faculty Speaker, CHW Cardiology Council Meeting, "Drug-Eluting Stents: Balancing Benefits and Risks", Pasadena, March 1, 2007.
190. Invited Faculty Speaker, FDA Workshop on Drug-Eluting Stents, CRT 2007. "Drug-Eluting Stents: Balancing Benefits and Risks", Washington DC, March 7, 2007.
191. Invited Speaker, Department of Pharmacy Continued Education Course. "Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease". Cedars-Sinai Medical Center, Los Angeles, CA, March 15, 2007.
192. Invited Distinguished Lecturer. Dayton Heart Hospital Foundation's Distinguished Lecturer Series. "Drug-eluting stents Controversy". Dayton, Ohio, April 18, 2007.
193. Invited Faculty Speaker, Oregon ACC Cardiovascular Symposium. "Cardiology Crossfire: Approaches to Multivessel CAD" Portland, Oregon, April 20, 2007.
194. Invited Faculty Speaker, Oregon ACC Cardiovascular Symposium. "Bare is Better: Why we need to reconsider DES?" Portland, Oregon, April 20, 2007.
195. Invited Faculty, AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2007: Quality of Care and Outcomes Soapbox: Debating the Extremes – Controversial View on How to Improve Healthcare: "Quantitative Standards of Clinical Importance. Expanding the Framework for Clinical Practice Guidelines" Washington DC, May 11, 2007.
196. Cardiology Grand Rounds. "Qualitative and Quantitative Standards of Care: Expanding the Framework for Clinical Practice Guidelines" Cedars-Sinai Medical Center, Los Angeles, CA,

May 22, 2007.

197. Invited Faculty Speaker, American Society of Echocardiography's 18th Annual Scientific Sessions. "Who is Vulnerable: Plaque Profile" Seattle, WA June 16, 2007.
198. Invited Faculty Speaker, American Society of Echocardiography's 18th Annual Scientific Sessions. "Clinical Profiles of Secondary Vulnerability and Progression: The Atheromatous Vessel" Seattle, WA June 16, 2007.
199. Invited Faculty Speaker, American Diabetes Association 67th Annual Scientific Sessions. "Testing for Cardiac Ischemia in People with Diabetes" Chicago, IL, June 22, 2007.
200. Invited Faculty Speaker, 13<sup>th</sup> World Congress on Heart Disease, International Academy of Cardiology Annual Scientific Sessions 2007. Drug-Eluting Stents: Is the Increased Risk of Stent Thrombosis an Acceptable Clinical Tradeoff for Reduced Restenosis? Vancouver, BC., Canada. July 28-31, 2007.
201. Invited Speaker. FDA Advisory Panel on Cardiovascular Effects of Rosiglitazone. "Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes: Alternative Interpretation of the Evidence". Gaithersburg, MD, July 30, 2007.
202. Cardiology Grand Rounds. "*Nessun dorma*. Have the Risks of Rosiglitazone Been Exaggerated?" Cedars-Sinai Medical Center, Los Angeles, CA, August 21, 2007.
203. Cardiology Grand Rounds, "What Cardiologists Should Know About Antithrombotic Therapy?" Cedars-Sinai Medical Center, Los Angeles, CA, September 10, 2007.
204. Invited Faculty Speaker, North American Thrombosis Summit "Antithrombotic Therapy for Acute Coronary Syndrome: Expanding the Framework for Clinical Practice Guidelines" Brigham and Women's Hospital, Boston, MA, September 28-29, 2007.
205. Endocrinology Grand Rounds. "The Rosiglitazone Story: Insights Gained and Implications" Cedars-Sinai Medical Center, Los Angeles, CA, October 2, 2007
206. Invited Faculty Speaker, Controversies in Cardiovascular Care Symposium. "Debate, antagonist: "Every patient with ACS should have coronary angiography & intervention", Los Angeles, CA, October 5, 2007.
207. Invited Faculty Speaker, ACC, California Chapter, Fellows in Training Forum: "How to Critically Evaluate Evidence and Apply to Clinical Practice?" Los Angeles, CA, October 6, 2007.
208. Invited Faculty Speaker, 2007 COAST Conference (Cardiovascular Medicine, Other Alternatives, and Surgical Therapies): "Management of Acute Coronary Syndrome", Kaiser-Permanente, Monterey, CA October 7, 2007.
209. Invited Faculty Speaker, Korean Society of Circulation: "Optimal Management of ACS with Antiplatelet Agents". Seoul, South Korea, October 11-13, 2007.
210. Invited Faculty Speaker, The 5th International Meeting on Intensive Cardiac Care. Debate, antagonist: "Every patient with NSTEMI ACS should have coronary angiography & intervention", Tel Aviv, Israel. October 14-16, 2007.
211. Invited Faculty Speaker, The 5th International Meeting on Intensive Cardiac Care. Debate, antagonist: "Drug eluting stents are safe and should be used in most patients", Tel Aviv, Israel. October 14-16, 2007.

212. Invited Faculty Speaker, XIX<sup>th</sup> Transcatheter Therapeutics Symposium. Washington DC, October 19-22 2007 (5 lectures).
213. Invited Chair, AHA Annual Scientific Sessions, Orlando, FA: "Understanding the Literature: Caveats in Interpreting New Evidence" November 4-7, 2007.
214. Invited Faculty Speaker, AHA Annual Scientific Sessions, Orlando, FA: Understanding the Literature: Caveats in Interpreting New Evidence: "Interpretation of Mega Trials 2", November 4-7, 2007.
215. Cardiology Grand Rounds, "Antithrombotic Therapy: An Update from the AHA Scientific Sessions" Cedars-Sinai Medical Center, Los Angeles, CA, November 13, 2007.
216. Invited Speaker, "From Evidence to Guideline: A Bayesian Approach", ACC/AHA Task Force on Practice Guidelines, Washington DC, December 6, 2007.
217. Medicine Grand Rounds. "Management of Stable Coronary Artery Disease". Roosevelt Hospital Center, New York City, NY, December 20, 2007.
218. Cardiology Grand Rounds. "Caveats in the Interpretation of Megatrials". St. Luke's Hospital, New York City, NY, December 20, 2007.
219. Medicine Grand Rounds, "Statistical Significance vs Clinical Importance: A Cautionary Tale About Clinical Practice Guidelines" Cedars-Sinai Medical Center, Los Angeles, CA, January, 2008.
220. Cardiology Grand Rounds, "Role of PCI in the Management of CAD: Evidence-Base or Enthusiasm-Bound?" Cedars-Sinai Medical Center, Los Angeles, CA, January 22, 2008.
221. Cardiology Grand Rounds, "An Update on Drug-eluting Stents" VA Medical Center, Los Angeles, CA, February 13, 2008.
222. Surgery Grand Rounds, "Plavix in the Perioperative Settings". Cedars-Sinai Medical Center, Los Angeles, CA, March 19, 2008
223. Invited Speaker, Department of Pharmacy Continued Education Course, "Plavix in the Perioperative Settings". Cedars-Sinai Medical Center, Los Angeles, CA, April 23, 2008
224. Invited Chair and Faculty, AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2008: "Workshop: How to Evaluate Therapeutic Effectiveness from Registry Data?" Baltimore, MD April 30, 2008.
225. Invited Chair, AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2008: Concurrent Session: Turbocharging the Guidelines. "Bayesian Classification of Guidelines". Baltimore, MD, May 1, 2008.
226. Cardiology Fellow Rounds. "Interpretation of Clinical Trials". UC San Diego Medical Center, San Diego, CA, May 12, 2008.
227. Cardiology Grand Rounds, "Role of PCI in the Management of CAD: Evidence-Base or Enthusiasm-Bound" UC San Diego Medical Center, San Diego, CA, May 12, 2008.
228. Endocrinology Grand Rounds. "Have the Risks of Rosiglitazone Been Exaggerated?" VA Medical Center, Los Angeles, CA, May 16, 2008.



229. Cardiology Grand Rounds, "An Update on Antithrombotic Therapy" Cedars-Sinai Medical Center, Los Angeles, CA, June 10, 2008.
230. Invited Faculty Speaker, Controversies in Cardiovascular Care Symposium. Cross Fire: "Multivessel CAD, Medical Protagonist". Los Angeles, CA, September 4, 5, 2008.
231. Invited Faculty Speaker, Controversies in Cardiovascular Care Symposium. Debate: "Does PCI save lives? Antagonist". Los Angeles, CA, September 4, 5, 2008.
232. Invited Faculty Speaker, Controversies in Cardiovascular Care Symposium. Debate: "Coronary Microvascular Disease: Real Disease Entity That Requires Specific Treatment Antagonist". Los Angeles, CA, September 4, 5, 2008.
233. Invited Faculty Speaker, ACC, California Chapter, Fellows in Training Forum: "Understanding the Literature: Caveats in Interpreting New Evidence" Los Angeles, CA, September 6, 2008.
234. Anesthesia Grand Rounds, "Plavix in the Perioperative Settings". Cedars-Sinai Medical Center, Los Angeles, CA, October 1, 2008.
235. Invited Faculty Speaker, ACC Lecture Series, Shanghai Fudan University. Shanghai, China, October 22, 2008
236. Invited Faculty Speaker, ACC Symposium, Cardiology Update 2008, Great Wall International Congress of Cardiology: "Prevention of CVD: Today and Tomorrow: Risk Factors and the Global Burden of Disease". Beijing, China, October 24, 2008
237. Invited Faculty Speaker, Canadian Cardiovascular Congress. "The Value of Evidence-Based Guidelines in Closing the Care Gap", Toronto, Canada, October 27, 2008.
238. Invited Faculty Speaker, AHA Annual Scientific Sessions, New Orleans, LA: How to Read the Medical Literature. "Interpreting Meta-analyses", November 9, 2008.
239. Cardiology Grand Rounds, "An Update on Important Clinical Trials: JPAD, TIMACS and JUPITER" Cedars-Sinai Medical Center, Los Angeles, CA, December 2, 2008.
240. Invited Faculty Speaker, NC20971 US Investigator meeting, "Lessons from Trials with Other HDL Raising Therapies", Phoenix, AZ, January 15, 2009.
241. Atherosclerotic cardiovascular Disease from path physiology to Management-New Insights. "Stable Angina and CAD: medical Management rather than PCI Should be the Focus". Cedars-Sinai Medical Center, Los Angeles, CA, January 16, 2009.
242. Invited Faculty Speaker, ACC i2.Symposium. "Debate: Should Left Main PCI/Stents No longer Be A Class III Guideline Recommendation?" Still Class III, Orlando, FL, March 30, 2009.

**MEDIA HITS (July 2007 to current)**

**THEHEART.ORG/MEDSCAPE/WebMD/HeartWire (the preeminent cardiology/medical news site)**

1. JUPITER hits New Orleans: Landmark study shows statins benefit healthy individuals with high CRP levels. Nov 9, 2008.
2. JUPITER casts a large shadow: Moving from efficacy data to the big picture. November 9, 2008.
3. More than half of stable CAD patients go straight to PCI without stress test. October 14, 2008.
4. Vytorin Rides Out Choppy SEAS. September 2, 2008
5. ATLAS trial "flaws"? Wall Street Journal alleges stats do not prove noninferiority of Liberté to Taxus Express. August 14, 2008
6. COURAGE quality-of-life analysis: Slim early gains with PCI soon disappear. August 13, 2008
7. Cardiologists put their oar into rocky SEAS and debate the results. July 24, 2008.
8. FDA delays prasugrel decision, Jun 26, 2008 09:00 EDT.
9. Bivalirudin "nonapprovable" for ACUITY indication, May 28, 2008 16:00 EDT.
10. HORIZONS published: Bivalirudin benefits in STEMI , May 21, 2008 17:00 EDT
11. Discrepancies in US/European guidelines on antithrombotics for ACS May 15, 2008 18:30 EDT.
12. ONTARGET: Clear messages from well-conducted study Apr 1, 2008 09:30 EDT.
13. ENHANCE published, presented, discussed, and debated: Experts mull over what the findings mean Mar 30, 2008 13:00 EDT
14. No increased death, MI with DES in randomized trials and registries, "mega"-meta-analysis suggests Mar 29, 2008 09:00 EDT
15. Questions about nonfatal MI in TRITON Mar 20, 2008 12:00 EDT
16. Questions arise about the chronology of events in the ENHANCE trial Jan 31, 2008 12:00 EST
17. Fewer deaths, MI, with CABG than DES for multivessel disease in NY State Jan 23, 2008 17:00 EST
18. ENHANCE saga continues: Experts dispute ezetimibe's future and "weight" of imaging studies Jan 16, 2008 14:45 EST
19. Have the Risks of Rosiglitazone Been Exaggerated? Journal Article, Future Cardiol, January 2008
20. Meta-analysis shows statins reduce all-cause mortality 22% in elderly CHD patients Jan 3, 2008 16:45 EST
21. Further evidence of CV harm with rosiglitazone Dec 11, 2007 16:00 EST

22. Rosiglitazone to stay on US market with new warnings about MI Nov 14, 2007 17:15 EST
23. TRITON-TIMI 38: Prasugrel lowers events but ups bleeding vs clopidogrel Nov 4, 2007 08:00 EST
24. Implementing Evidence-Based Medicine Through Medicare Coverage Decisions .Journal Article, Health Aff, November 2007
25. HORIZONS AMI: Bivalirudin reduces bleeding, adverse clinical events in STEMI Oct 24, 2007 17:45 EDT
26. Glitazones increase heart failure but not mortality in new meta-analysis Sep 27, 2007 18:30 EDT
27. Interventional cardiologists tackle COURAGE Sep 14, 2007 17:30 EDT
28. Mortality similar with drug-eluting and bare-metal stents at four years, but sirolimus stent "clinically superior" Sep 13, 2007 18:30 EDT
29. Fresh fuel for the glitazone controversy: New pioglitazone and rosiglitazone meta-analyses Sep 11, 2007 16:15 EDT
30. Rosiglitazone wrangling continues in NEJM correspondence Aug 29, 2007 17:00 EDT
31. Reanalysis of Nissen/Wolski rosiglitazone meta-analysis scrutinizes findings, methods Aug 8, 2007 17:00 EDT
32. DES have lost gloss, not value, experts conclude in special stent-thrombosis issue of JACC Jul 4, 2007 08:30 EDT.

#### **NEWSPAPERS/MAGAZINE/TV/Internet Web**

33. **Forbes:** A new age of statins. November 13, 2008.
34. **Forbes:** Cardiologist questions safety of Lilly's prasugrel. November 10, 2008
35. **Forbes:** More Delays For Lilly's Heart Drug. October 17, 2008
36. **Forbes:** Pay for Proof. October 13, 2008
37. **Forbes:** Another Storm Brewing For Vytarin. August 27, 2008
38. Rosiglitazone: one year later. Endocrine Today, NJ - Jun 25, 2008.
39. **ABC News:** Cardiologist Questions Safety of Lilly's Prasugrel, November 11, 2008.  
<http://abcnews.go.com/Health/wireStory?id=6230595>
40. **Reuters News:** Cardiologist Questions Safety of Lilly's Prasugrel, November 11, 2008.  
<http://de.reuters.com/article/idUKN1047750720081111>.
41. **BNET Pharma:** More Bad News for Lilly's Prasugrel. November 11, 2008.  
<http://industry.bnet.com/pharma/1000380/more-bad-news-for-lillys-prasugrel/>

42. **NPR:** Are All Those Angioplasties Necessary? October 15, 2008.  
[www.npr.org/templates/story/story.php?storyId=95720324](http://www.npr.org/templates/story/story.php?storyId=95720324)
43. **LA Times:** 2 drugs might have no benefit, By Don Costello LA Times Reporter March 31, 2008.  
<http://articles.latimes.com/2008/mar/31/business/fi-heart31>
44. **Washington Post, ABC News:** Death Rate High in Drug-Coated Stent Trial. By Ed Edelson HealthDay Reporter, Tuesday, July 10, 2007; 12:00 AM. [http://www.washingtonpost.com/wp-dyn/content/article/2007/07/10/AR2007071000740\\_pf.html](http://www.washingtonpost.com/wp-dyn/content/article/2007/07/10/AR2007071000740_pf.html)
45. **Forbes:** Experts Speak On Vytorin Study: Forbes discussed the controversial ENHANCE study with more than a dozen cardiologists. Here are some opinions. March 31, 2008
46. **Forbes:** The Vytorin Consensus: Schering and Merck may not be as villainous as critics claim. For investors, it may not matter January 23, 2008.
47. **Forbes:** Eli Lilly's Big Battle: New data dims outlook for the company's most important experimental drug. November 04, 2007
48. **Forbes:** Eli Lilly Faces Battle Over Blood Thinner: New data dims outlook for the company's most important experimental drug. November 04, 2007
49. **Forbes:** Big Scary Guesses: When it comes to drug safety, how do you decide how risky is too risky? September 11, 2007
50. **Forbes:** Merck's Good Cholesterol Battle: New data are due out on a promising cholesterol drug. But there are doubters. August 30, 2007
51. **Forbes:** Good Cholesterol Goes Bad: The drug industry makes \$35 billion selling cholesterol-lowering drugs. But its attempts to come up with an encore have failed. April 16, 2007.
52. **ScienceDaily:** Reanalysis Of Controversial Meta-analysis Says Writing Off Rosiglitazone May Be Premature. Aug. 10, 2007.
53. **AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2008 Highlighted Presentations:** Turbocharging the Guidelines moderated by Sanjay Kaul, May 1 2008.
54. **CNBC:** FDA delaying a decision on whether to approve Eli Lilly's blood thinner Effient. . M Huckman. July 3, 2008.
55. **CNBC:** The Vytorin Saga. M Huckman. March 31, 2008
56. **The HealthCare Channel:** Cardiology Panel on Multivessel CAD, moderated by Sanjay Kaul. October 18, 2008
57. **The HealthCare Channel:** A Critique of the Prasugrel TRITON TIMI-38 Trial by Sanjay Kaul. March 11, 2008
58. **The HealthCare Channel:** Cardiology Panel on CABG vs DES, Part 1 and 2 moderated by Sanjay Kaul. February 12, 2008

59. **The HealthCare Channel:** Stent Debate: Late Stent Thrombosis, Sanjay Kaul and Gregg Stone. December 21, 2007
60. **The HealthCare Channel:** Stent Debate: Xience Stent, Sanjay Kaul and Gregg Stone. December 21, 2007
61. **The HealthCare Channel:** Stent Debate: COURAGE Trial, Sanjay Kaul and Gregg Stone. December 21, 2007
62. **The HealthCare Channel:** Stent Debate: The Registries, Sanjay Kaul and Gregg Stone. December 21, 2007
63. **The HealthCare Channel:** Stent Safety with Dr. Sanjay Kaul. November 20, 2007
64. **Clinicaltrialresults.org:** Drs. Gibson and Kaul comment on JUPITER, COURAGE and ENHANCE Trials. November 2008
65. **Clinicaltrialresults.org:** Drs. Diamond and Kaul comment on the criticism and controversy surrounding the COURAGE Trial. August 2007
66. **Clinicaltrialresults.org:** Drs. Diamond and Kaul comment on the criticism and controversy surrounding the Rosiglitazone meta-analysis. September 2007
67. **Clinicaltrialresults.org:** Drs. Gibson, Stone and Kaul discuss the HORIZON Trial. November 2007
68. **Clinicaltrialresults.org:** Drs. Gibson, Stone and Kaul discuss the TIMI-38 TRITON Trial. November 2007
69. **Clinicaltrialresults.org:** Drs. Gibson, Stone and Kaul discuss Bayesian Analysis of Clinical Trials. November 2007
70. **American College of Cardiology, Conversation with the Experts, Cardiosource Video Network (CVN):** PCI vs. Medical Therapy in Chronic Coronary Artery Disease by Drs. Hutter, Boden and Kaul. November 10, 2008.
71. **American College of Cardiology Cardiosource Video Network (CVN):** COURAGE Trial Reassessed by Drs. Diamond and Kaul. October 16, 2007.
72. **American College of Cardiology Cardiosource Video Network (CVN):** Effect of Rosiglitazone: Alternative Interpretations of the Evidence by Drs. Diamond and Kaul. August 29, 2007.
73. **American College of Cardiology Cardiosource Video Network (CVN):** Quality of Care and Outcomes Research Conference 2007. July 11, 2007

#### **PRESENTATIONS (No published Abstracts)**

1. **Kaul S**, Waack BJ Brooks RM, and Heistad DD: Altered Vascular Responses to Platelets from Hypercholesterolemic Humans. Presented at the 2nd International Symposium on Heart Failure - Mechanisms and Management, Geneva, Switzerland, May 16-20, 1993.
2. **Kaul S**, and Heistad DD: Altered Vascular Responses to Platelets from Hypercholesterolemic Humans. Presented at the 5th International Symposium on Mechanisms of Vasodilatation, IUPS, Glasgow, Scotland, August, 1993.

3. **Kaul S**, Waack BJ, Brooks RM, and Heistad DD: Effect of Lipoproteins on Vascular Responses to Platelets. Slide talk presented at the AHA, Laverna Titus Young Investigator's Forum, Los Angeles, California, May 1994.
4. **Kaul S**, Naqvi TZ, Fishbein MC, Cercek B, Molloy MD, Forrester JS, Hutsell TC, and Shah PK: Profound Inhibition of Arterial Thrombosis by a Novel Nitric Oxide Donor. Presented at the AHA Scientific Conference on the Functional and Structural Aspects of the Vascular Wall, Salt Lake City, Utah, February 1995. (**\*Young Investigator Award**)
5. Naqvi TZ, Fishbein MC, Thomas AM, Cercek B, Molloy MD, Hutsell TC, Shah PK, and **Kaul S**: Restoration of Thromboresistance in Injured Aortic Segments by a Novel Nitric Oxide Donor. Presented at the AHA Scientific Conference on the Functional and Structural Aspects of the Vessel wall, Salt Lake City, Utah, February 1995.
6. **Kaul S**, Naqvi TZ, Fishbein MC, Cercek B, Molloy MD, Hutsell TC, Forrester JS, and Shah PK: Profound inhibition of arterial injury-induced thrombosis by a novel nitric oxide donor. Presented at the 3rd International Congress on Heart Failure in Geneva, Switzerland, May 1995.
7. Naqvi TZ, Shah PK, Fishbein MC, Molloy MD, Hutsell TC, and **Kaul S**: Arterial injury-induced thrombus formation in hypercholesterolemic humans: Protective effect of HDL. (**\*Young Investigator Award**), Laverna Titus Young Investigator's Forum, AHA, Los Angeles, CA, May 1995.
8. **Kaul S**, Naqvi TZ, Fishbein MD, Molloy MD, Hutsell TC, and Shah PK: Effects on nitric oxide donors on arterial injury-induced thrombus formation in humans. Finalist, Laverna Titus Young Investigator Award, AHA, Los Angeles, CA., May 1995.
9. Nilsson J, Regnstrom J, Ameli S, Calara R, Nilsson AH, Cercek B, Yano J, **Kaul S**, Shah PK: Immunization of Cholesterol-Fed Rabbits with Oxidized LDL Reduces Arterial Intimal Thickening After Balloon Injury (Presented at Joint Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Salt Lake City, UT, Feb 1996).
10. Regnstrom J, Nilsson J, Yhip P, Cercek B, Faire de U, Ericson CG, **Kaul S**, Hamsten A, Shah PK: Reduced serum paraoxonase activity is associated with angiographic progression of atherosclerosis and new clinical events in young survivors of acute myocardial infarction: Bezafibrate Coronary Atherosclerosis Intervention Trial (Presented at Joint Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Salt Lake City, UT, Feb 1996).
11. **Kaul S**, Regnstrom J, Molloy MD, Yamashita M, Yano J, Fishbein MC, Shah PK, Hutsell TC, Cercek B: A unique NO donor reduces smooth muscle proliferation and neointimal thickening by inhibiting arterial-injury associated nuclear factor- $\kappa$ B activation (Presented at Joint Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Salt Lake City, UT, Feb 1996).
12. Makkar R, Eigler, NL, Nakamura M, Litvack FI, Badimon L, Jordan R, Bramfitt J, **Kaul S**: Monoclonal antibody to IIb-IIIa receptor (m7E3) is highly effective in inhibiting acute stent thrombosis (Presented at Transcatheter Cardiovascular Therapeutics, Washington D.C., March 1996).
13. Makkar R, Eigler NL, Nakamura M, Litvack FI, Badimon JJ, Molloy MD, Bramfitt J, Hutsell TC, **Kaul S**: Marked inhibition of acute stent thrombosis by a novel nitric oxide donor (Presented at Transcatheter Cardiovascular Therapeutics, Washington D.C., March 1996).
14. Naqvi TZ, Ivy PA, Linn P, Israeli ML, Shah PK, Cercek B, **Kaul S**: Effects of Heparin on Platelet Function in Patients with Coronary Artery Disease (Finalist, Laverna Titus Young Investigator's Forum, AHA, Los Angeles, CA, May 1996).

15. Makkar R, Eigler NL, Nakamura M, Litvack FI, Badimon JJ, Molloy MD, Bramfitt J, Hutsell TC, **Kaul S**: Marked inhibition of acute stent thrombosis by a novel nitric oxide donor (Finalist, Laverna Titus Young Investigator's Forum, AHA, Los Angeles, CA, May 1996).
16. **Kaul S**, Xu XP, Sharifi B, Dimayuga P, Radpavar K, Shah PK, Cercek B: Nitric Oxide Donor Inhibits Mechanical Injury-Induced Activation and Expression of Nuclear Factor-kappa B in Cultured Vascular Smooth Muscle Cells (Finalist, Laverna Titus Young Investigator's Forum, AHA, Los Angeles, CA, May 1996).48.
17. Shechter M, Bairey-Merz N, Rude RK, Paul-Labrador M, Molloy MD, **Kaul S**: Intracellular magnesium deficiency promotes arterial thrombus formation in patients with coronary artery disease. (Presented ACC, Anaheim 1997; and the Laverna Titus Young Investigator Award Competition of the AHA, Greater LA, May 28, 1997).
18. Hedayati-Rad A, Coin BD, Molloy MD, Cercek B, Shah PK, **Kaul S**: Inhibitors of reactive oxygen species suppress LDL-induced augmentation of platelet aggregation. (Presented at the Laverna Titus Young Investigator Award Competition of the AHA, Greater LA, May 28, 1997)
19. Coin BD, Shah PK, Yano J, Molloy MD, Cercek B, **Kaul S**: Recombinant apolipoprotein A-I Milano protects against lysophosphatidylcholine-induced endothelial dysfunction. (Presented at the Laverna Titus Young Investigator Award Competition of the AHA, Greater LA, May 28, 1997)
20. **Kaul S**, Terhakopian A, Cercek B, Yano J, Sinaii N, Shah PK: Intrapericardial Apolipoprotein A-I<sub>Milano</sub> Reduces Intimal and Adventitial Hyperplasia in Porcine Coronary Overstretch Injury Model (Presented at the Xth TCT Conference, Washington DC, October 1998).
21. Makkar R, Shah PK, Terhakopian A, Cercek B, Fishbein MC, Sinaii N, **Kaul S**: Intrapericardial Delivery of a Nitric Oxide Donor Inhibits In-Stent Stenosis in Porcine Coronary Arteries. The Xth TCT Conference, Washington DC, October 1998.

#### AREAS OF RESEARCH INTEREST:

1. Bayesian Inference in Medicine.
  - a. Bayesian analysis of clinical trials.
  - b. Bayesian classification of clinical practice guidelines.
2. Cardiovascular Quality and Outcomes
  - a. Impact of clinical importance on therapeutic decision making and guideline adherence.
  - b. Evidence-based reimbursement as a strategy for healthcare reform.
3. Stent Thrombosis and Restenosis
  - a. Kinetic modeling of restenosis, thrombosis and clinical outcomes.
  - b. Magnesium as a therapeutic strategy against stent thrombosis.
  - c. Effect of Apolipoprotein A-1 Milano on Drug-eluting Stent Thrombosis
4. Vascular Biology of Atherothrombosis
  - a. Antiatherogenic Effects of High Density Lipoprotein and its apolipoproteins.
  - b. Vascular Response to Arterial Injury: Role of Nitric Oxide
  - c. Gene Transfer to Modulate Vascular Response to Injury
5. Modulation of Vascular Tone by Endothelium
6. Role of Antithrombotic agents in Stable and Unstable Coronary Artery Disease

#### CURRENT PROJECTS:

1. Development of a Bayesian tool to help analyze and interpret clinical trials and formulate clinical practice guidelines.
2. Develop and validate a kinetic model of restenosis, thrombosis and clinical outcomes post-stenting.
3. Effects of Magnesium sulfate on stent thrombosis.
4. Effects of Systemic, Intramural and Intrapericardial Delivery of Apolipoprotein-A<sub>I</sub> Milano (mutant apolipoprotein A1) on Vascular Response to Balloon Overstretch and Stent Implantation Injury of Porcine Coronary Arteries.
5. Effects of Apolipoprotein-A<sub>I</sub> Milano (mutant apolipoprotein A1) on stent thrombosis

#### TEACHING ACTIVITIES:

1. Cedars-Sinai Medical Center

1999 - present	Director, Cardiology Fellowship Training Program
1996 – 2006	Associate Director, Coronary Care Unit,
1995 - 2000	ACLS Introductory lecture on Acute MI (5-6 lectures per year)
1994 - present	Director, Cardiology Consult Service
1993 - present	Attending Staff on the CCU & the Cardiology Ward Services (5-6 months per year)
1993 - 1998	Medical Students Physical Diagnosis Rounds
1993 - present	Emergency Lecture Series to Medicine House Staff (1-2 per year)
1993 - present	Core Curricula Lecture Series to the CCU House staff and Cardiology Fellows (20-25 per year)
2. University of Iowa Hospitals & Clinic

1990 - 1993:	Instructor, Introduction to Clinical Medicine; attending, clinical teaching ward
--------------	---



## PUBLICATIONS/BIBLIOGRAPHY:

### RESEARCH PAPERS:

#### RESEARCH PAPERS - PEER-REVIEWED

1. **Kaul S**, Heistad DD, Mugge A, Armstrong ML, Piegors DJ, and Lopez JAG: Vascular Responses to Platelet Activation in Normal and Atherosclerotic Primates in Vivo. *Arterioscler Thromb* 1991;11:1745-1751
2. **Kaul S**, Waack BJ, and Heistad DD: Asymmetry of Vascular Responses in Perfused Rabbit Carotid Artery to Intraluminal and Abluminal Vasoactive Stimuli. *J. Physiol* (London) 1992;458:223-234
3. **Kaul S**, Padgett RC, Waack BJ, Brooks RM, and Heistad DD: Vascular Responses to Human Platelets in Atherosclerotic and Normal Carotid Arteries. *Arteriosclerosis Thromb* 1992;12:1206-1213
4. **Kaul S**, Padgett RC, Waack BJ, Brooks RM, and Heistad DD: Altered Vascular Responses to Platelets from Hypercholesterolemic Humans. *Circ. Res* 1993;72:737-743
5. Ameli S, **Kaul S**, Arora C, Castro L, Mirea A, and Shah PK: Altered Circulating Levels of Endothelin, Atrial Natriuretic Peptide, Epinephrine and Norepinephrine Post Coronary Angioplasty. *Am. J. Cardiol* 1993;72:1352-1356
6. **Kaul S**, Padgett RC, and Heistad DD: Role of Platelets and Leukocytes in Modulation of Vascular Tone. *Ann. NY Acad. Sci* 1994;714:122-133
7. **Kaul S**, Waack BJ, Padgett RC, Brooks RM, and Heistad DD: Interaction of Leukocytes with Platelets in Modulation of Vascular of Vascular Responses in Perfused Arteries. *Am. J. Physiol* 1994;35:H1706-H1714
8. Benzuly KH, Padgett RC, **Kaul S**, Piegors DJ, Armstrong ML, and Heistad DD: Functional Improvement Precedes Structural Regression of Atherosclerosis. *Circulation* 1994;89:1810-1818
9. Tadokoro H, Miyazaki A, Satomura K, **Kaul S**, Kar S, Corday E, and Drury K: Infarct Size Reduction with Coronary Venous Retroinfusion of Diltiazem in the Acute Occlusion/Reperfusion Porcine Heart Model. *J. Cardiovasc. Pharmacol* 1996;28:134-141
10. **Kaul S**, Makkar RR, Nakamura M, Litvack FI, Shah PK, Forrester JS, Hutsell TC, Eigler NL: Inhibition of Acute Stent Thrombosis Under High-Shear Flow Conditions by a Nitric Oxide Donor, DMHD/NO: An Ex Vivo Porcine Arteriovenous Shunt Study. *Circulation* 1996;94:2228- 2234
11. Makkar RR, Litvack FI, Eigler NL, Nakamura M, Ivey PA, Forrester JS, Shah PK, **Kaul S**: Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. *Circulation* 1997;95:1015-1021
12. Yumi K, Fagin JA, Fishbein MC, Shah PK, **Kaul S**, Forrester JS, Nilsson J, Cercek B: Inhibitory effects of somatostatin analog octreotide on vascular insulin-like growth factor-I gene expression and neointimal proliferation following arterial balloon injury in rats. *Lab Invest* 1997;76:329-338
13. Cercek B, Dimayuga P, Shah PK, Nilsson J, **Kaul S**, Regnstrom J: Transcription factor NF-kB after arterial balloon injury. *Atherosclerosis* 1997;131:59-66

14. **Kaul S**, Naqvi TZ, Fishbein MC, Cercek B, Badimon JJ, Hutsell TC, Thomas S, Molloy M, Shah PK: Local delivery of an ultra-short-acting nitric oxide-releasing compound, DMHD/NO, is highly effective in inhibiting acute platelet-thrombus formation on injured arterial strips. *J Cardiovasc Pharmacol Ther* 1997;2(3):181-194
15. Shah PK., Nilsson J, **Kaul S**, Fishbein MC, Ageland H, Hamsten A, Cercek B: Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. *Circulation* 1998;97:780-785
16. Chaux A, Ruan XM, Fishbein MC, Ouyang Y, **Kaul S**, Pass JA, Matloff JM: Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. *J Thorac Cardiovasc Surg*, 1998;115:604-614
17. Naqvi TZ, Shah PK, Ivey PA, Molloy MD, Linn P, Linker-Israeli M, Cercek B, **Kaul S**: Therapeutic Concentrations of Heparin Potentiate Platelet Activation at the Time of Coronary Angiography. *J Cardiovasc Pharmacol Ther* 1998;3:91-102
18. Makkar R, Eigler NL, **Kaul S**, Nakamura M, Litvack FI, Forrester JS, Herbert JM, Litvack FI: Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. *Eur Heart J* 1998;19:1538-1546
19. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, **Kaul S**, Russell RO Jr, Zusman RM, Forrester JS, Douglas PS, Faxon DP, Fisher JD, Gibbons RJ, Halperin JL, Hochman JS, Weintraub WS, Winters WL Jr, Wolk MJ: Use of sildenafil (Viagra) in patients with cardiovascular disease. *Circulation* 1999;99:168-77, and *J Am Coll Cardiol* 1999, 33:1:273-282
20. **Kaul S**, Forrester JS.: Role of Routine Angiography and Revascularization in Patients with Non-Q-Wave MI. (*Evidence-Based Cardiovascular Medicine* January Issue 1999).
21. Rajavashisth T, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fishbein MC, **Kaul S**, Cercek B, Sharifi B, Shah PK: Membrane type 1-matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory Mediators. *Circulation* 1999;99:3103-3109
22. Xu X-P, Meisel SR, Ong JM, **Kaul S**, Cercek B, Tripathi RB, Sharifi BG, Shah PK: Oxidized low density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. *Circulation* 1999;99:993-998
23. Wallner K, Chen Li, Shah PK, Fishbein MC, Forrester JS, **Kaul S**, Sharifi BG: Expression of tenascin C in human coronary atherosclerotic plaque. *Circulation* 1999;99:1284-1289
24. Tripathi RB, Xu XP, Meisel S, Xu H, Fishbein MC, **Kaul S**, Cercek B, Sharifi B, Shah PK: Membrane-Type Matrix Metalloproteinase-1 is Expressed in Human Atherosclerotic Plaques: Evidence for Activation by Pro-inflammatory Mediators. *Circulation* 1999;99:3103-3109
25. Shechter M, Bairey-Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Cercek B, Shah PK, **Kaul S**: Oral Magnesium Supplementation Inhibits Platelet-Dependent Thrombosis in Patients with Coronary Artery Disease. *Am J Cardiol* 1999;84:152-156
26. Yamashita M, Dimayuga P, **Kaul S**, Shah PK, Regnstrom J, Nilsson J, Cercek B: Phosphatase activity in the arterial wall following balloon injury: effect of somatostatin analog octreotide. *Lab Invest* 1999;79:935-944
27. Naqvi TZ, Fishbein MD, Molloy MD, Shah PK, Cercek B, **Kaul S**: HDL Cholesterol is an Independent Predictor of Acute Platelet-Dependent Thrombus Formation. *Am J Cardiol*

1999;84:1011-1017

28. Chyu KY, Dimayuga P, Zhu J, Calara F, Nilsson J, **Kaul S**, Shah PK, Cercek B: Decreased intimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice *Circ Res* 1999;85:1192-1198
29. **Kaul S**, Cercek B, Regnstrom J, Lake JP, Yano J, Xu XP, Dimayuga P, Tripathi RB, Shah, PK: Polymeric-Based Periadventitial Delivery of a Nitric Oxide Donor Inhibits Intimal Hyperplasia After Balloon-Induced Arterial Injury: Role of Nuclear Factor- $\kappa$ B. *J Am Coll Cardiol* 2000;35:493-501
30. Shechter M, Bairey-Merz CN, Paul-Labrador M, **Kaul S**: Blood Glucose and Platelet-Dependent Thrombosis in Coronary Artery Disease Patients. *J Am Coll Cardiol* 2000;35:300-307
31. Shechter M, Bairey-Merz CN, Paul-Labrador M, **Kaul S**: Plasma Apolipoprotein B Levels Predict Platelet-Dependent Thrombosis in Coronary Artery Disease Patients. *Cardiology* 2000;92(3):151-155
32. **Kaul S**, Shah PK: Low-Molecular-Weight Heparin in Acute Coronary Syndrome: Evidence for Superior or Equivalent Efficacy Compared to Unfractionated Heparin? *J Am Coll Cardiol* 2000;35:1699-712
33. Bowman A, Dhar S, Siegel R, Blanche C, **Kaul S**: Metastatic Pancreatic adenocarcinoma to the heart diagnosed antemortem. *J Am Soc Echocardiogr* 2000;13:415-6
34. DeBusk R, Drory Y, Goldstein I, Jackson G, **Kaul S**, Kimmel S, Kostis J, Kloner R, Lakin M, Meston C, Mittleman M, Muller J, Padma-Nathan H, Rosen R, Stein R, Zusman R: Management of Sexual Dysfunction in Patients with Cardiovascular Disease: Recommendations of the Princeton Consensus Panel. *Am J Cardiol* 2000;86:62F-68F
35. Forrester JS, Bairey-Merz CN, **Kaul S**: The Aggressive LDL-Lowering Controversy. *J Am Coll Cardiol* 2000;36:1419-25
36. Shechter M, Bairey-Merz CN, Paul-Labrador M, **Kaul S**: Intracellular Magnesium Levels Predict Platelet-Dependent Thrombosis in Coronary Artery Disease Patients *Am Heart J* 2000;140:212-8
37. Matetzky S, Shah PK, Eigler NM, **Kaul S**, Cercek B: Prognostic Value of Troponin I in patients undergoing Primary Angioplasty. *Circulation* 2000;102:1611-1616
38. Shechter M, Bairey-Merz CN, Paul-Labrador M, **Kaul S**: Blood Glucose and Platelet-Dependent Thrombosis in Coronary Artery Disease Patients. *Cardiology Review* 2000;17:25-28
39. Remskar M, Li H, Shah PK, Cercek B, Yano J, Reyes O, Chyu KY, **Kaul S**, Bisgaier CL, Drake S, Cercek B: Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury. *Circ Res* 2001;88:390-4
40. Shah PK, Yano J, Reyes O, Chyu KY, **Kaul S**, Bisgaier CL, Drake S, Cercek B: High-dose recombinant apolipoprotein a-i(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice : potential implications for acute plaque stabilization. *Circulation* 2001;103:3047-50

41. Rukshin V, Azarbal B, Shah PK, Tsang VT, Shechter M, Cercek B, **Kaul S**: Intravenous Magnesium In Experimental Stent Thrombosis In Swine. *Arterioscler Thromb Vasc Biol* 2001;21:1544-1549.
42. Matetzky S, Sharir T, Noc M, Domingo M, Chyu K-C, Kar S, Eigler N, **Kaul S**, Shah PK, Cercek B: Primary Angioplasty for Acute Myocardial Infarction in Octogenarians. *American Journal of Cardiology*. 88(6):680-683, September 15, 2001
43. Shah PK **Kaul S**, Cercek B: Improving outcomes in unstable angina. *Emergency Medicine* 2001;33:48-61
44. Xu XH, Shah, PK, Faure E, Thomas L, Luthrigger D, Xu XP, Yano J, **Kaul S**, Cercek B, Arditi M: Toll-Like Receptor-4 is Expressed in Human Coronary Atherosclerotic Plaques and Upregulated by Oxidized Low Density Lipoprotein in Macrophages. *Circulation* 2001;104:3103-3108.
45. Shah PK, **Kaul S**, Nillson J, Cercek, B: Exploiting the Protective Effects of HDL: An Idea Whose Time For Testing Is Here. *Circulation* 2001;104: 2376-2383.
46. Shah PK, **Kaul S**, Nillson J, Cercek, B: Exploiting the Protective Effects of HDL: An Idea Whose Time For Testing Is Here. *Circulation* 2001;104: 2498-2502.
47. Swissa M, Ohara T, Lee M-H, **Kaul S**, Shah PK, Chen P-S, Karagueuzian HS: High concentration Sildenafil and Nitric Oxide donor combination promotes the induction of ventricular tachycardia and ventricular fibrillation in the isolated-perfused normal swine right ventricle. *Am J Physiol* 2002 282: p. H1787-1792.
48. Meisel SR, Xu XP, Edgington TS, Dimayuga P, **Kaul S**, Lee S, Fishbein MC, Cercek B, Shah PK: Differentiation of adherent human monocytes into macrophages markedly enhances tissue factor protein expression and procoagulant activity. *Atherosclerosis* 2002;161:35-43
49. Rukshin V, Shah PK, Tsang VT, Cercek B, **Kaul S**: Comparative Antithrombotic Effects Of Magnesium And Platelet Gp IIb-IIIa Inhibitors, Tirofiban and Eptifibatide, In A Canine Model Of Stent Thrombosis. *Circulation* 2002; 105: 1970-75.
50. Matetzky S, Domingo M, Noc M, Kar S, Shah PK, **Kaul S**, Daar E, Cercek B: Acute Myocardial infarction in young HIV-positive patients. *Arch Intern Med* 2003;163:457-460.
51. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, Maurere G, Mahrer P, **Kaul S** et al for AZACS Investigators. The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome. The AZACS (Azithromycin in Acute Coronary Syndrome) trial. *Lancet* 2003;361:809-813.
52. Rukshin V, Azarbal B, Shah PK, Tsang VT, Shechter M, Cercek B, **Kaul S**: Dethrombotic Effects of Tirofiban: An Ex Vivo Study of Stent Thrombosis in Canine. *J Cardiovasc Pharmacol* 2003;41:615-24.
53. **Kaul S**, Rukshin V, Tsang VT, Cercek B, Shah PK: Intramural Delivery of Recombinant Apolipoprotein A-IMilano/ Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries. *Circulation* 2003;107:2551-4.
54. Rukshin V, Makkar R, Gheorghiu M, Kar S, Santos R, Padmanabhan S, Azarbal B, Eigler N, Lepor N, Khorsandi M, Buchbinder NA, Samuels B, Tsang VT, **Kaul S**: A Prospective Non-Randomized, Open-Labeled Pilot Study Investigating The Use Of Magnesium In Patients Undergoing Non-Acute Percutaneous Coronary Intervention With Stent Implantation. *J*

*Cardiovasc Pharmacol & Therap* 2003;8:193-200.

55. Naghavi M, Libby P, Falk E, ..... **Kaul S**, Shah PK, Willerson JT: From Vulnerable Plaque to Vulnerable Patient: A Call for New Definition and Risk Assessment Strategies: Parts I, *Circulation* 2003;108:1664-1772.
56. Naghavi M, Libby P, Falk E, ..... **Kaul S**, Shah PK, Willerson JT: From Vulnerable Plaque to Vulnerable Patient: A Call for New Definition and Risk Assessment Strategies: Parts II, *Circulation* 2003;108:1772-8.
57. Neuman Y, Rukshin V, Tsang V, Atar S, Miyamoto T, Luo H, Kobal S, Thompson T, Yochai Birnbaum Y, Horzewski M, Siegel RJ, **Kaul S**: Augmentation of In-Stent Clot Dissolution by Low Frequency Ultrasound Combined with Aspirin and Heparin: An Ex-Vivo Canine Arteriovenous Shunt Study. *Thromb Res.* 2003;112:99-104.
58. Diamond GA, **Kaul S**: Prior Convictions: Bayesian Approaches to the Analysis and Interpretation of Randomized Clinical Trials. *J Am Coll Cardiol.* 2004;43:1929-39.
59. Anazawa T, Dimayuga P, Li H, Tani S, Bradfield J, Chyu K-Y, **Kaul S**, Shah PK, Cercek B. Effect of exposure to cigarette smoke on carotid artery intimal thickening: the role of inducible nitric oxide synthase. *Arterioscler Thromb Vasc Biol.* 2004; 24:1652-58.
60. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, **Kaul S**, Shah PK. Differential Effects of Apolipoprotein A-I-Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice. *Circulation* 2004;110:1701-05.
61. **Kaul S**, Coin B, Hedayiti A, Yano, J, Chyu KC, Cercek B, Shah PK: Rapid Reversal of Endothelial Dysfunction in Hypercholesterolemic Apo E-Null Mice by Recombinant Apolipoprotein A-IMilano-Phospholipid Complex. *J Am Coll Cardiol.* 2004;44:1311-19.
62. **Kaul S**, Diamond GA, Weintraub WS: Trials and Tribulations of Non-inferiority: The Ximelagatran Example. *J Am Coll Cardiol.* State of the Art Paper. 2005 46: 1986-1995.
63. **Kaul S**, Shah PK: ApoA-I Milano/phospholipid Complexes. Emerging Pharmacological Strategies and Medications for the Prevention of Atherosclerotic Plaque Progression. *Current Drug Targets - Cardiovascular & Hematological Disorders*, 2005;5:471-479.
64. Diamond GA, **Kaul S**: Hazardous to Your Health: Quantitative Kinetic Foundations of Risk Stratification and Therapeutic Triage. *Am J Med.* 2006;119:275.e1-275.e6.
65. Tung, R, **Kaul S**, Diamond, GA, Shah PK: Narrative Review: Drug-eluting Stents for the Management of Restenosis: A Critical Appraisal of the Evidence. *Ann Int. Med.* 2006;144:913-9.
66. **Kaul S**, Diamond GA: Good Enough: A Primer on Analysis of Active Control Non-Inferiority Clinical Trials. *Ann Int. Med.* 2006;145:62-9.
67. Naghavi M, Falk, E, **Kaul S**, ..... Shah PK et al. From Vulnerable Plaque to Vulnerable Patient – Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. *Am J Cardiol.* 2006;98(2A):2H-15H.
68. **Kaul S**, Zadeh, AA, Shah, PK: Does Homocysteine Promote Atherothrombotic Cardiovascular Disease? Deconstructing the Evidence. (*J Am Coll Cardiol* 2006;48:914-923).

69. **Kaul S**, Diamond GA: Drug-eluting stents: An ounce of prevention for a pound of flesh? Editorial. (*Cardiosource*, 2006).
70. **Kaul S**, Diamond GA: Non Making Sense of Noninferiority: A Clinical and Statistical Perspective on its Application to Cardiovascular Clinical Trials. *Progress in Cardiovascular Disease* 2007;49:284-299.
71. Diamond GA, **Kaul S**: From Here to Eternity: Pathophysiological Kinetics of Atherosclerotic Events. *Am J Med* 2007;120:5-11.
72. Diamond GA, **Kaul S**: An Orwellian Discourse on Non-inferiority: Its Meaning and Measurement. *Am J Cardiol* 2007;99:284-287.
73. Eshaghian S, **Kaul S**, Amin S, Shah PK, Diamond GA. Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease. *Ann Int. Med.* 2007;146:434-41.
74. Diamond GA, **Kaul S**: The Things to Come of SHAPE: Cost and Effectiveness of Cardiovascular Prevention. *Am J Cardiol.* 2007;99:1013-5. Epub 2007 Feb 15.
75. **Kaul S**, Reducing Inflammatory Biomarkers: What Does it Mean? *Cardiology Review* 2007;24:34-35.
76. Diamond GA, **Kaul S**, Shah PK: Screen Testing: Cardiovascular Prevention in Asymptomatic Diabetics. *J Am Coll Cardiol* 2007; 49:1915-1917.
77. **Kaul S**, Shah PK, Diamond GA. State-of-the-Art-Paper: As Time Goes By: Current Status and Future Directions in the Controversy over Stenting. *J Am Coll Cardiol* 2007;50:128-37. Epub 2007 May 22. Expedited Review and Publication.
78. **Kaul S**: Drug-eluting Stents Controversy: Current Status and Future Directions. *Am Heart Hosp J* 2007 Summer; 5(3):165-8.
79. Diamond GA, Bax L, **Kaul S**: Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death. *Ann Intern Med.* 2007;147; 578-581
80. Diamond GA, **Kaul S**: COURAGE Under Fire: On the Management of Chronic Stable Angina. *J Am Coll Cardiol.* 2007;16;50(16):1604-9.
81. Eshaghian S, **Kaul S**, Shah PK. "Cardiac Amyloidosis: New Insights in to Diagnosis and Management". *Rev in Cardiovasc Med* 2007; 8(4):189-99.
82. Diamond GA, **Kaul S**: Prevention and Treatment: A Tale of Two Strategies. *J Am Coll Cardiol* 2008; 51:46-48,
83. **Kaul S**, Diamond GA: "Have the risks of rosiglitazone been exaggerated?" *Future Cardiology* 2008;4 (1):9-13.
84. **Kaul S**: "Biomarkers in Heart Failure: Work in Progress". Invited Commentary, *Cardiology Review*, March 2008.
85. Das J, **Kaul S**. "Is homocysteine a relevant cardiovascular risk factor? *Current Cardiovascular Risk Reports* 2008;2:141-149.

86. Taggart DP, **Kaul S**, Ferguson B, Guyton R, Mack M, Sergeant P, Shemin R, Smith PK, Yusuf S. Revascularisation for Unprotected Left Main Stem Coronary Artery Stenosis: Stenting or Surgery. *J Am Coll Cardiol*. 2008;51:885-92.
87. **Kaul S**, Diamond GA: "Rosiglitazone and Cardiovascular Risk". Invited Paper, *Curr Atheroscler Rep* 2008;5:398-404.
88. Diamond GA, **Kaul S**: The Disconnect between Practice Guidelines and Clinical Practice: Stressed Out. *JAMA* 2008;300:1817-18.

#### RESEARCH PAPERS - PEER REVIEWED (IN PRESS)

89. Diamond GA, **Kaul S**. Evidence-Based Financial Incentives for Health Care Reform: Putting it Together (In Press in *Circulation, Cardiovascular Quality and Outcomes*).
90. Diamond GA, **Kaul S**: Cost, Effectiveness and Cost-Effectiveness. (In Press in *Circulation, Cardiovascular Quality and Outcomes*).
91. Jeremias A, **Kaul S**, Gruberg L, Rosengart TK, Brown DL. The Impact of Percutaneous or Surgical Revascularization on Mortality in Patients with Stable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials. (In Press in *Am J Med*).

#### RESEARCH PAPERS - PEER REVIEWED (SUBMITTED)

92. Diamond GA, **Kaul S**, Boden WE. A 300 Year Old Solution to the Health Care Crisis. (In Review, *Archives of Internal Medicine*).
93. **Kaul S**: Invited Editorial on "Impact of Plaque Composition on Cardiac Troponin Elevation After Percutaneous Coronary Intervention: A Virtual Histology-Intravascular Ultrasound Analysis". (Invited Editorial, *J Am Coll Cardiol. Cardiovascular Imaging*).
94. Houle FA, Hinsberg WD, **Kaul S**, Diamond GA. A change of heart: a kinetic model of clinical outcomes following coronary stenting. (In Review, *Nature Clinical Practice Cardiovascular Medicine*).
95. Diamond GA, **Kaul S**: "Bayesian Classification for Clinical Practice Guidelines". (In Review, *Archives of internal Medicine*,)
96. Bolger A, **Kaul S**, Herrington D, Giugliano R, Eckel R. ACC/AHA Science Advisory on Thiazolidinediones. (In Review *Circulation* and *JACC*).
97. **Kaul S**, Diamond GA: "Interpretation of Megatrials II" (Invited State of the Art Paper, *J Am Coll Cardiol*)
98. **Kaul S**, Diamond GA. HyperACUITY: Determinants of Quality in the Assessment of Noninferiority (In Review in *J Am Coll Cardiol*).
99. Yusuf S, Karthikeyan G, Taggart D, **Kaul S**, Bogaty P, Brophy J, Weintraub W, Boden WE. Role of percutaneous coronary intervention in coronary disease—time for a critical re-appraisal (In Review in *Lancet*)

100. **Kaul S**, Terhakopian A, Sinai N, Rukshin V, Makkar R, Yano, J, Chyu KC, Cercek B, Shah PK: Intrapericardial Apo A-I<sub>Milano</sub> Reduces Intimal and Adventitial Hyperplasia in Porcine Coronary Overstretch Injury Model. (In Review, *JACC Intervention*).
101. **Kaul S**, Diamond GA: Non-inferiority lies in the eyes of the beholder: Reassessment of TAXUS ATLAS trial". (In Review, *JACC*).
102. Chou S, Eshaghian S, Dohad S, Lamer A, Tran H, **Kaul S**. Glycoprotein 2b/3a Inhibitor Bridging Therapy in the Perioperative Management of Patients with Drug-Eluting Stents. (In Review, *Cardiovascular Reviews*).
103. Spertus JA, Rumsfeld JS, Krumholz HM, **Kaul S**, Diamond GA, Peterson ED, Drozda Jr. JP, Radform MJ, Normand SLT, Chan P, Masoudi FA, ACCF/AHA Task Force on Performance Measures Methodology Document on New Insights into the Methodology of Performance Measurement: A report of the ACC/AHA Task Force on Performance Measures Methodology Document (Writing Committee of the ACC/AHA Task Force on Performance Measures Methodology Document on New Insights into the Methodology of Performance Measurement). *J Am Coll Cardiol*.
104. Jesse R, **Kaul S**, Diamond GA, Gersh B, Newby K, Philippides G, McKay C, Weintarub W, Christenson R, Fesmire F, Babb J, DeFer TM. ACCF/AHA clinical expert consensus document on Practical Clinical Considerations in the Interpretation of Troponin Elevations: A report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (Writing Committee of the Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations). *J Am Coll Cardiol*.
105. Morrissey R, Diamond GA, **Kaul S**:. "Statins in ACS: Do the Guidelines Match the Evidence?" (*J Am Coll Cardiol*)

## **CHAPTERS**

1. **Kaul S**: Hypercoagulable States in the Coronary Care Unit, in Mohsenifar Z, Shah, PK, Rubin L., (eds). *Practical Critical Care in Cardiology* (Marcel Dekker, New York) 1997.
2. Price MJ, **Kaul S**: Homocysteine in CHD, in Shah, PK (eds). *Risk Factors in CAD*, 2001.
3. Zadeh AA, Price MJ, **Kaul S**: Homocysteine in CHD: An Update, in Shah, PK (eds). *Risk Factors in CAD*, 2006.
4. **Kaul S**, Forrester JS: :Erectile Dysfunction and the Cardiovascular System in James Willerson J, Cohn J, Wellens H, and Holmes D, (eds). *Cardiovascular Medicine, Third Edition* (Springer, UK). 2007
5. **Kaul S**: Platelet Glycoprotein 2b/3a Inhibitors. Kipshidze's (eds). *Textbook of Interventional Cardiovascular Pharmacology*. 2007.
6. Das J, **Kaul S**. Chapter: Homocysteine Hypothesis for Cardiovascular Diseases. Masella, Roberta and Giuseppe Mazza. *Glutathione and Sulfur Amino Acids in Human Health and Disease*. ISBN 978-0-470-17085-4. Hardcover, 512 pg John Wiley and Sons, 2008 (*In Press*).



7. Das J, **Kaul S**. In-hospital Management of STEMI. Ischemic Heart Disease, Crawford, DiMarco & Paulus's Cardiology, Third Edition. Elsevier (*In Press*).
8. Kedia G, **Kaul S**. Acute and Late Stent Thrombosis. Ischemic Heart Disease, Crawford, DiMarco & Paulus's *Cardiology*, Third Edition.Elsevier (*In Press*).
9. **Kaul S**, Diamond GA. "A Time to live". Naghavi (ed). Textbook of "Subclinical Atherosclerosis: Detection,Treatment, and Monitoring of Asymptomatic Individuals Susceptible to Atherosclerosis and Vulnerable to Cardiovascular Events" (Springer, UK) (In Press)
10. Diamond GA, **Kaul S**: "Dynamic Changes in Risk as the Basis for Therapeutic Triage". Naghavi (ed). Textbook of "Subclinical Atherosclerosis: Detection,Treatment, and Monitoring of Asymptomatic Individuals Susceptible to Atherosclerosis and Vulnerable to Cardiovascular Events" (Springer, UK) (In Press)

#### **REVIEWS, EDITORIALS & LETTERS TO THE EDITOR**

1. **Kaul S**, Fishbein M, and Siegel RJ: Cardiac Manifestations of AIDS; 1991 Update. *Am. Heart J* 1999;122:535-544
2. Shammass NW, **Kaul S**, Stuhlmuller JE, and Ferguson DW: Traumatic Mitral Insufficiency Complicating Blunt Chest Trauma Treated Medically - Case Report and Review. *Crit. Care Med* 1992;20(7):1064-1068
3. Swan HJC, **Kaul S**: Revascularization for Acute Myocardial Infarction: Thrombolytic Therapy or Angioplasty - Still a Burning Question. *Fibrinolysis and Proteolysis* 1998;12:5-11.
4. Response to Letter to the Editor. Re: **Kaul S**, Diamond GA, Weintraub WS: Trials and Tribulations of Non-inferiority: The Ximelagatran Example. *J Am Coll Cardiol*. 2006;48.1059.
5. Response to Letter to the Editor. Re: **Kaul S**, Zadeh, AA, Shah, PK: Does Homocysteine Promote Atherothrombotic Cardiovascular Disease? Deconstructing the Evidence. (*J Am Coll Cardiol*. 2007; 49;1371).
6. Diamond GA, **Kaul S**, Shah PK. The Logic of Risk Stratification. Letter to the Editor . Re: Beller GA. Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients: Is it appropriate and cost-effective? *J Am Coll Cardiol* 2007; 49:1918-1923
7. Diamond GA, **Kaul S** Letters to the Editor. Rosiglitazone and Cardiovascular Risk. *N Engl J Med* 2007;357:937-940.
8. Response to Letter to the Editor. Re: Diamond GA, **Kaul S**: The Things to Come of SHAPE: Cost and Effectiveness of Cardiovascular Prevention. *Am J Cardiol*. 2007;100:1494-5.
9. Diamond GA, **Kaul S** Letters to the Editor. Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med* 2008;359:530.
10. Response to Letter to the Editor. Re: Meliga etal. :Percutaneous Coronary Intervention or CABG for Unprotected Left Main CAD: The Endless Debate. **Kaul S**, Ferguson B, Guyton R, Mack M, Sergeant P, Shemin R, Smith PK, Yusuf S, Taggart DP, Revascularisation for Unprotected Left Main Stem Coronary Artery Stenosis: Stenting or Surgery. *J Am Coll Cardiol*. 2008;52:584-85.

11. **Kaul S**. "Cardiac catheterization in higher-risk non-ST Elevation ACS—why it is underutilized by physicians?" Invited Commentary, (In Press, *Cardiology Review*).
12. **Kaul S, Diamond GA**. Letters to the Editor. JUPITER trial. *N Engl J Med* (In Review).

#### **PAPERS IN PREPARATIONS (RESEARCH COMPLETED)**

- 1.
- 2.
- 3.
- 4.
- 5.

#### **ABSTRACTS**

1. Tadokoro H, Miyazaki A, Satomura K, **Kaul S**, Fishbein M, Corday E, and Drury J: Profound Infarct Size Reduction with Coronary Venous Retroinfusion of Diltiazem in Pigs. *J. Am. Coll. Cardiol* 1988;11(2):87A
2. **Kaul S**, Waack BJ, Mugge A, Padgett RC, Lopez JAG, and Heistad DD: Vascular Responses to Human Platelets: Intraluminal vs. Abluminal Activation. *FASEB J* 1991;5(4):A523
3. **Kaul S**, Waack BJ, Mugge A, Brooks RM, Lopez JAG, and Heistad DD: Altered Vascular Responses to Activated Platelets from Hypercholesterolemic Humans. *Clin. Res* 1991;39(2):253A
4. Ameli S, **Kaul S**, Arora C, Mirea A, Castro L, Sharifi B, Antonescu A, and Shah PK: Coronary Angioplasty Increases Circulating Endothelin Levels. *Clin. Res* 1991;39(2):368A
5. **Kaul S**, Ameli S, Arora C, Castro L, Mirea A, and Shah PK: Does PTCA Increase Circulating Endothelin Level in Man? *Circulation* 1991;84(Suppl. II):II-726
6. **Kaul S**, Waack BJ, Brooks RM, and Heistad DD: Altered Vascular Responses to Activated Platelets from Hypercholesterolemic Humans. *Stroke* 1992;23:153
7. **Kaul S**, Waack BJ, and Heistad DD: Mechanisms of Asymmetric Vascular Responses to Purinergic Agonists in Perfused Carotid Artery. *FASEB J* 1992;6(4):A1457

8. Ameli S, **Kaul S**, Mirea A, Arora C, Czer L, and Shah PK: Transient Increase in Circulating Endothelin Levels Following Orthotopic Cardiac Transplantation. *Clin. Res* 1992;4-(2):234A
9. Benzuly KH, Padgett RC, **Kaul S**, Piegors DJ, Armstrong ML, and Heistad DD: Hyperresponsiveness to Serotonin Subsides Rapidly During Regression of Atherosclerosis. *Circulation* 1992;86(4):1-158
10. **Kaul S**, Waack BJ, Brooks RM, and Heistad DD: Interaction of Human Platelets and Leukocytes in Modulation of Carotid Vascular Tone, *Stroke* 1993;24:182
11. **Kaul S**, Waack BJ, Padgett RC, Brooks RM, and Heistad DD: Effects of Aging on Responses of Perfused Carotid Artery to Human Platelets. *FASEB J* 1993;7:A861
12. **Kaul S**, Benzuly KH, Padgett RC, Piegors DD, and Heistad DD: Vascular Responses to Activation of Platelets after Regression of Atherosclerosis. *Clin Res* 1993;41:(2):216A
13. **Kaul S**, Waack BJ, Brooks RM, and Heistad DD: Altered Vascular Responses to Platelets from Hypercholesterolemic Humans. Presented at the 2nd International Symposium on Heart Failure Mechanisms and Management, Geneva Switzerland, May 16-20, 1993.
14. **Kaul S**, Waack BJ, Brooks RM, and Heistad DD: Effects of Aging on Responses of Perfused Carotid Artery to Human Platelets. *Circulation* 1993;88:(4):1983
15. **Kaul S**, Waack BJ, Brooks RM, and Heistad DD: Effects of Low Density Lipoproteins on Vascular Response to Platelets. *J. Am Coll Cardiol* 1994;64A:717-5
16. **Kaul S**, Waack BJ, Brooks RM, and Heistad DD: Mechanisms of Impaired Vasodilator Responses to Platelets from Hypercholesterolemic Humans. *Circulation* 1994;90:(4):3102
17. **Kaul S**, Naqvi TZ, Fishbein MC, Cercek B, Molly MD, Forrester JS, Hutsell TC, and Shah PK: Profound Inhibition of Arterial Thrombosis by a Novel Nitric Oxide Donor. Abstract # 44, AHA Scientific Conference on the Functional and Structural Aspects of the Vascular Wall, Salt Lake City, Utah, February 1-4 1995.
18. Naqvi TZ, Fishbein MC, Thomas AM, Cercek B, Molloy MD, Hutsell TC, Shah PK, and **Kaul S**: Restoration of Thromboresistance in Injured Aortic Segments by a Novel Nitric Oxide Donor. Abstract # 45, AHA Scientific Conference on the Functional and Structural Aspects of the Vascular Wall, Salt Lake City, Utah, February 1-4 1995.
19. **Kaul S**, Naqvi TZ, Fishbein MC, Cercek B, Malloy MD, Forrester JS, Hutsell TC, and Shah PK: Profound Inhibition of Arterial Thrombosis by a Novel Nitric Oxide Donor. *J. Am Coll Cardiol* 1995;34A:901-121
20. Naqvi TZ, Fishbein MC, Thomas AM, Cercek B, Molloy MD, Hutsell TC, Shah PK and **Kaul S**: Restoration of Thromboresistance in Injured Aortic Segments by a Novel Nitric Oxide Donor. *J. Am Coll Cardiol* 1995;382A:797-3
21. **Kaul S**, Naqvi TZ, Fishbein MC, Forrester JS, Malloy MD, Badimon JJ, Hutsell TC, and Shah PK: Profound Inhibition of Arterial Thrombosis by a Novel Nitric Oxide Donor. *The J. of Heart Failure* Vol 2, 1995;(1), 416
22. **Kaul S**, Naqvi TZ, Panicker S, Cercek B, Malloy MD, Forrester JS, Hutsell TC, Shah PK: Comparative effects of nitric oxide donors and aspirin on ex-vivo platelet-thrombus formation in normal and hypercholesterolemic rabbits. *Circulation* 1995;92:(8):2982

23. Naqvi TZ, Ivy PA, Linn P, Israeli ML, **Kaul S**, Shah PK: Low dose heparin enhances and high dose heparin suppresses platelet P-selectin expression and platelet aggregation. *Circulation* 1995;92(8):3230
24. **Kaul S**, Regnstrom J, Lake JP, Yano J, Yamashita M, Forrester JS, Shah PK, Hutsell TC, Cercek B: Marked antiproliferative effects of locally delivered nitric oxide donor. *Circulation* 1995;92(8):1103
25. Makkar R, Eigler NL, Nakamura M, Litvack FI, Badimon JJ, Molloy MD, Bramfitt J, Hutsell TC, **Kaul S**: Marked inhibition of acute stent thrombosis by a novel nitric oxide donor. *Circulation* 1995;92(8):3296
26. Makkar R, **Kaul S**, Nakamura M, Dev V, Litvack FI, Park K, McPherson Badimon JJ, Sheth SS, Eigler NL: Modulation of acute stent thrombosis by metal surface characteristics and shear rate. *Circulation* 1995;92(8):0410
27. Makkar R, Eigler NL, Nakamura M, Litvack FI, Badimon L, Jordan R, Bramfitt J, **Kaul S**: Monoclonal antibody to IIb-IIIa receptor (m7E3) is highly effective in inhibiting acute stent thrombosis. *Circulation* 1995;92(8):3291
28. **Kaul S**, Naqvi TZ, Cercek B, Fishbein MC, Molloy MD, Badimon L, Hutsell TC, Shah PK: Profound inhibition of arterial-injury induced thrombosis in normal and hypercholesterolemic humans by nitric oxide donors: An ex-vivo study. *Circulation* 1995;92(8):2011
29. Naqvi TZ, Shah PK, Badimon JJ, Cercek B, Forrester JS, Molloy MD, **Kaul S**: Variable effects of lipids on arterial injury-induced thrombus formation. *Circulation* 1995;92(8):3334
30. Regnstrom J, Yamashita M, Dimayuga P, Zhu J, Lake JP, Shah PK, **Kaul S**, Nilsson J, Cercek B: Arterial activation of nuclear Factor- $\kappa$ B following balloon injury in rats. *Circulation* 1995;92(8):1094
31. Makkar R, Nakamura M, Eigler N, Herbert JM, Zeng H, Litvack F, **Kaul S**: Clopidogrel is More Effective than Aspirin in Inhibiting Acute Stent Thrombosis. *J. Am Coll Cardiol* 1996;27(22):333A
32. Regnstrom J, Nilsson J, Yhip P, Cercek B, Faire de U, Ericson CG, **Kaul S**, Hamsten A, Shah PK: Reduced serum paraoxonase activity is associated with angiographic progression of atherosclerosis and new clinical events in young survivors of acute myocardial infarction: Bezafibrate Coronary Atherosclerosis Intervention Trial. *J. Am Coll Cardiol* 1996;27(22):185A
33. Ivey PA, Naqvi TZ, Shah PK, Cercek B, Hutsell TC, **Kaul S**: Suppression of Contrast-Mediated Platelet Activation by a Nitric Oxide (NO) Donor, an NO Adduct of methylhexanediamine. *J Invest Med* 1996;44(3):249A
34. Xu XP, **Kaul S**, Cercek B, Sharifi B, Dimayuga P, Radpavar K, Shah PK: Nitric Oxide Donor Inhibits Mechanical Injury-Induced Activation and Expression of Nuclear Factor-kappa B in Cultured Vascular Smooth Muscle Cells. *J Invest Med* 1996;44(3):243A
35. Xu XP, Meisel SR, Cercek B, Ong JM, **Kaul S**, Sharifi B, Radpavar K, Shah, PK: Differential effects of modified low density lipoprotein on matrix metalloproteinases and their tissue inhibitors in human monocyte-derived macrophases. *Circulation* 1996;94:I-396
36. Xu XP, Cercek B, Meisel SR, Dimayuga P, Sharifi B, Ong JM, Radpavar K, Shah PK, **Kaul S**: Nitric oxide donor suppresses vascular smooth muscle cell proliferation via inhibition of

- nuclear factor kappa-B. *Circulation* 1996;94:I-472
37. Yamashita M, Dimayuga P, Yano J, Shah PK, Nilsson J, **Kaul S**, Cercek B: Inhibition of protein phosphatases by okadaic acid enhances vascular fox/jun and nuclear factor Kappa-B activation in vivo. *Circulation* 1996;94:I-524
  38. Naqvi TZ, Ivey PA, Molloy MD, Linn P, **Kaul S**: Heparin attenuates nitric oxide-mediated suppression of platelet activation *Circulation* 1996;94:I-743
  39. Makkar R, Litvack FI, **Kaul S**, Eigler NL, Nakamura M, Fishbein MC, Eigler NL: Microscopic mechanisms of stent thrombosis: Role of 7E3 antibody. *Circulation*
  40. Meisel SR, Xu XP, **Kaul S**, Cercek B, Radparvar K, Lee S, Shah PK: A long-acting nitric oxide donor suppresses basal and lipopolysaccharide-stimulated tissue factor procoagulant activity in human monocyte-derived macrophages. *J Am Coll Cardiol* 1997;29:265A
  41. Schechter M, Bairey-Merz N, Rude RK, Paul-Labrador M, Shah PK, Cercek B, **Kaul S**: Intracellular magnesium predicts functional capacity in patients with coronary artery disease. *J Am Coll Cardiol* 1997;29:379A
  42. Shechter M, Bairey-Merz N, Rude RK, Paul-Labrador M, Molloy MD, **Kaul S**: Low Intracellular magnesium deficiency promotes arterial thrombus formation in patients with coronary artery disease. *J Am Coll Cardiol* 1997;29:179A
  43. Makkar R, Litvack FI, **Kaul S**, Zeng H, Eigler NL: High-shear overrides the antithrombotic effects of aspirin on stent thrombosis *J Am Coll Cardiol* 1997;29:354A
  44. Makkar R, Eigler NL, **Kaul S**, Litvack FI: Integrated mechanisms of experimental stent thrombosis. *J Am Coll Cardiol* 1997;29:94A
  45. Makkar R, **Kaul S**, Zeng H, Herbert JM, Eigler NL, Litvack FI: Clopidogrel, a novel platelet ADP-receptor antagonist inhibits aspirin and ticlopidine-resistant stent thrombosis. *J Am Coll Cardiol* 1997;29:353A
  46. Shechter M, Bairey-Merz N, Paul-Labrador M, Molloy MD, Agarwala A, **Kaul S**: Fasting Blood Sugar is Related to Platelet-Dependent Thrombosis in Patients with Coronary Artery Disease and Controlled Lipid Levels. *Circulation* 1997;96:I-438
  47. Chyu KY, Dimayuga P, **Kaul S**, Cercek B: Time-dependent expression of inducible nitric oxide synthase after mechanical injury. *Circulation* 1997;96:I-234
  48. Ong JM, Pan TH, **Kaul S**, Cercek B, Sharifi B, Nilsson J, de la Llera MM, Shah PK: Is Apolipoprotein A-I<sub>Milano</sub> more efficient in promoting cholesterol efflux than wild-type apolipoprotein A-I. *Circulation* 1997;96:I-661
  49. Oguchi S, Dimayuga P, **Kaul S**, Shah PK, Cercek B: Increased intimal thickening after arterial injury in hypercholesterolemic apolipoprotein E-deficient mice: Finding in a novel model. *Circulation* 1997;96:I-548
  50. Coin BD, Shah PK, Yano J, Molloy MD, Cercek B, **Kaul S**: Reversal of Impaired Endothelium-Dependent Vasodilatation in Apolipoprotein E-deficient Mice by Recombinant Apolipoprotein A-I Milano. *J Am Coll Cardiol* 1998;31:60A
  51. Wallner K, Shah PK, Fishbein MC, Forrester JS, **Kaul S**, Sharifi BG: Expression of Tenascin-C in Human Coronary Atherosclerotic Plaque. *J Am Coll Cardiol* 1998;31:73A

52. Shechter M, Bairey-Merz CN, Paul-Labrador M, Molloy MD, Cercek B, Shah PK, **Kaul S**: Plasma Apolipoprotein B Levels Predict Platelet-Dependent Thrombosis in Patients with Coronary Artery Disease. *J Am Coll Cardiol* 1998;31:146A
53. Coin BD, Shah PK, Yano J, Molloy MD, Cercek B, **Kaul S**: Recombinant Apolipoprotein A-I Milano Protects Against Lysophosphatidylcholine-Induced Endothelial Dysfunction. *J Am Coll Cardiol* 1998;31:148A
54. Shah PK, Nilsson J, **Kaul S**, Yano J, Zhu J, Hamsten B, Cercek B: Inhibition of Aortic Atherosclerosis in Apolipoprotein E-deficient Mice by Recombinant Apolipoprotein A-I Milano. *J Am Coll Cardiol* 1998;31:390A
55. Xu XP, Ong JP, **Kaul S**, Cercek B, Sharifi B, Shah PK: A Novel membrane-Type Matrix Metalloproteinase (MT-MMP) is Expressed in Human Atherosclerotic Plaques and Localized in macrophages and Smooth Muscle Cells. *J Am Coll Cardiol* 1998;31:419A
56. Makkar, R.R., Shah, P.K., Terhakopian, A., Cercek, B., Fishbein, M.C., Sinaii, N., **Kaul, S.**: Intrapericardial Delivery of a Nitric Oxide Donor Inhibits In-Stent Stenosis in Porcine Coronary Arteries. *Circulation* 1998;98(17):I-399
57. **Kaul S**, Terhakopian A, Cercek B, Yano J, Sinaii N, Shah PK: Intrapericardial Apolipoprotein A-I<sup>Milano</sup> Reduces Intimal and Adventitial Hyperplasia in Porcine Coronary Overstretch Injury Model. *J Am Coll Cardiol* 1999;33(Suppl A):71A
58. **Kaul S**, Terhakopian A, Cercek B, Yano J, Sinaii N, Shah PK: Pharmacokinetic Profile of Intrapericardial Administration of NO Donors Critically Modulates the Vascular Response to Injury. *J Am Coll Cardiol* 1999;33(Suppl A):88A
59. Dimayuga P, Zhu J, **Kaul S**, Shah PK, Cercek B: Reduced Phosphatase Activity in the Arterial Wall Following Balloon Injury. *J Am Coll Cardiol* 1999;33(Suppl A):223A
60. Chyu KY, Dimayuga P, Zhu J, Yano J, **Kaul S**, Shah PK, Cercek B: Decreased Vascular Cell Adhesion Molecule-1 Expression And Neointimal Thickening After Arterial Injury In Inducible Nitric Oxide Synthase Knockout Mice. *Circulation* 1999;100:I-114
61. **Kaul S**, Cercek B, Shah PK: Low-Molecular-Weight Heparin in Acute Coronary Syndrome: Evidence for Superior or Equivalent Efficacy Compared to Unfractionated Heparin? *J Am Coll Cardiol* 2000;35(Suppl A):344A
62. Azarbal B, Miroka J, Shah PK, Cercek B, **Kaul S**: Adverse Cardiovascular Events Associated With the Use of Viagra. *J Am Coll Cardiol* 2000;35(Suppl A):553A
63. Xu XP, Xu XH, Chyu KY, Collins JM, Rajavashisth T, **Kaul S**, Cercek B, Shah, PK: Estrogen and Progesterone but not Tamoxifen Inhibit Oxidized Low Density Lipoprotein Induced Matrix Metalloproteinase-9 in Cultured Human Macrophages. *J Am Coll Cardiol* 2000;35(Suppl A):368A
64. Matetzky S, Tani S, Dimayuga P, Kangavari S, Zhu J, Xu H, Yano J, Chyu KY, Fishbein M, **Kaul S**, Shah, PK, Cercek, B: Cigarette Smoking Increases Tissue-Factor Expression in Human and Murine Atherosclerotic Plaques. *J Am Coll Cardiol* 2000;35(Suppl A):313A
65. Shechter M, Labrador MP, Merz CNB, **Kaul S**: Serum Glucose but Not Insulin Modulates Platelet-Dependent Thrombosis in Patients With Coronary Artery Disease. *J Am Coll Cardiol*. 2000;35(Suppl. A):281A.

66. Xu XH, Shah PK, Faure E, Thomas L, Luthrigger D, Xu XP, Yano J, **Kaul S**, Cercek B, Arditi M; Toll-Like Receptor-4 is Expressed in Human Coronary Atherosclerotic Plaques and Upregulated by Oxidized Low Density Lipoprotein in Macrophages. *J Am Coll Cardiol* 2000;35(Suppl. A):260A.
67. Xu XP, Chyu KY, Collins J, Xu XH, Harpf A, Cercek B, **Kaul S**, Rajavashisth TB, Shah PK; Estrogen and progesteron inhibit oxidized low density induced-induced matrix metalloproteinase-9 in cultured macrophages. *J Am Coll Cardiol* 2000;35:368A
68. Swissa M, Ohara T, Lee MH, **Kaul S**, Shah PK, Chen PS, Karagueuzian HS: High concentration Slidenafil and Nitric Oxide donor combination promotes the induction of ventricular tachycardia and ventricular fibrillation in the isolated-perfused normal swine right ventricle. *Circulation* AHA 2000.
69. Liu M, Chai NN, Shukla A, **Kaul S**, Shah PK, Cercek B, Rajavashisth TB: Absence of Neointimal Thickening Following Arterial Injury in M-CSF-Deficient Mice and Its Reversal by Local Delivery of M-CSF Highlights the Critical Role of M-CSF in Neointima Formation. *J Am Coll Cardiol* 2001;37(Suppl. A): Abstract 1187-9
70. Sharifi BG, Wu KG, Wang L, Rajavashsith T, **Kaul S**, Shah PK; Adeno-Associated Virus-Mediated Apo A-I Milano Genethrapy for Atherosclerosis and Restenosis. *J Am Coll Cardiol*. 2001;37(Suppl. A):1192-167
71. Shah PK, Yano J, Bisgaier CL, Reyes OS, Xu XH, McMurty MK, Drake S, **Kaul S**, Chyu KY, Cercek B; *J Am Coll Cardiol* 2001;37(Suppl. A):816-5.
72. Rukshin V, Azarbal B, Cercek B, Shah PK, Tsang V, **Kaul S**: Dethrombotic and Antithrombotic Effects of Glycoprotein 2b3a Inhibitor, Tirofiban, in an Ex Vivo Canine Stent Thrombosis Model. *J Am Coll Cardiol* 2001;37(Suppl. A):808-6.
73. Rukshin V, Azarbal B, Finkelstein A, Tsang VT, **Kaul S**: Comparative Antithrombotic Effects Of Magnesium And Platelet Gp IIb-IIIa Inhibitors, Tirofiban And Eptifibatide, In A Canine Model Of Stent Thrombosis (*AHA Scientific Session*, Anaheim, CA, 2001).
74. **Kaul S**, Rukshin V, Santos R, Azarbal B, Bisgaier C, Johansson J, Tsang VT, Chyu KY, Shah PK: Intramural Delivery Of Recombinant Apolipoprotein A-I <sup>Milano</sup>/Phospholipid Complex (Etc-216) Inhibits In-Stent Stenosis In Porcine Coronary Arteries (*AHA Scientific Session*, Anaheim, CA, 2001).
75. Anazawa T, Yano J, Zhao X, **Kaul S**, Dimayuga P, Chyu K-Y, Cercek B, Shah PK: Cigarette smoke creates an unstable aytherosclerotic plaque phenotype by enhancing vascular oxidative stress, increasing vascular endothelial growth factor expression and procucing collagen loss in apo E-/- mice. *J Am Coll Cardiol* 2002;39 (Suppl. A):258A.
76. Anazawa T, Li H, Yano J, Zhao X, **Kaul S**, Chyu K-Y, Shah PK, Cercek B: Selective inducible nitric oxide synthase inhibitor mercaptoethylguanidine attenuates neointimal formation in injured mice exposed to cigarette smoke. *J Am Coll Cardiol* 2002;39 (Suppl. A):258A.
77. Reyes OS, Chyu-CK, Yano J, Zhao X, Cercek B, **Kaul S**, Nillson J, Shah PK: Immunization with a novel human apo B100 related peptide reduces atherosclerosis and inflammation in apo E null mice. *J Am Coll Cardiol* 2002;39 (Suppl. A):240A.
78. **Kaul S**, Padmanabhan S, Price MJ, Diamond GA: Do Glycoprotein 2b3a Inhibitors Reduce Mortality?: A Bayesian Meta-Analysis. *J Am Coll Cardiol* 2002;39 (Suppl. A).

79. **Kaul S**, Price MJ, Padmanabhan S, Rukshin V, Diamond GA: Does The Evidence Support The Verdict Of High Profile Clinical Trials?: A Conventional Versus Bayesian Perspective *J Am Coll Cardiol* 2002;39 (Suppl. A).
80. Rajavashisth TB, Lui M, Tanaka H, Tripathi J, Tripathi P, Loussaranian A, Libby P, Uzal H, Kumar A, Doherty TM, Cercek B, **Kaul S**, Shah PK: Obligate Role of macrophage colony stimulating factor for the development of neointimal thickening following arterial injury. *J Am Coll Cardiol* 2003;41 (Suppl. A):34A.
81. Dimayuga PC, Anazawa T, Li H, Chyu K-Y, **Kaul S**, Shah PK, Cercek B. Altered innate and adaptive immune response following exposure to cigarette smoke: potential role in enhanced intimal thickening after injury. *Circulation* 108, IV-202, 2003.
82. **Kaul S**, Diamond GA. Are Claims of Non-inferiority of Ximelagatran Relative to Warfarin in SPORTIF-V Sufficiently Justified? (ACC Scientific Sessions, March 2005).
83. **Kaul S**, Diamond GA. Raising the Standard of Evidence for Noninferiority: A Review of Recent Clinical Trials. (AHA Scientific Sessions, November 2005 - Control/Tracking Number: 05-SS-A-20826-AHA).
84. **Kaul S**, Diamond GA. Is the Non-inferiority Claim for Bivalirudin in Percutaneous Coronary Intervention Warranted? REPLACE-2 Revisited. (ACC Scientific Sessions, March 2006).
85. **Kaul S**, Zadeh AA, Diamond GA, Shah PK. Does Homocysteine Lowering Impact Cardiovascular Outcomes? A Bayesian Meta-Analysis of NORVIT and HOPE-2 Trials. (Accepted for AHA 2006, Control/Tracking Number: 06-SS-A-10496-AHA).
86. **Kaul S**, Shah PK, Diamond GA. Bivalirudin During Early Invasive Strategy for Acute Coronary Syndromes: Noninferiority in ACUTY Lies in the Eyes of the Beholder. (Accepted for AHA 2006, Control/Tracking Number: 06-SS-A-11744-AHA).
87. **Kaul S**, Tung RH, Diamond GA, Shah PK. Are Drug-Eluting Stents Really Worth The Money? Disconnect Between Clinical Trials and Clinical Practice Estimates. (Accepted for AHA 2006, Control/Tracking Number: 06-SS-A-13927-AHA).
88. Eshaghian S, Amin S, Shah PK, Diamond GA, **Kaul S**. Does Clopidogrel Provide Clinically Important Benefit in Atherothrombotic Cardiovascular Disease? A Bayesian Perspective. (Accepted for AHA 2006, Control/Tracking Number: 06-SS-A-13927-AHA).
- Kaul S**, Diamond GA. "Virtual Superiority": A New Composite Score for Grading the Quality of Noninferiority Cardiovascular Clinical Trials. American College of Cardiology 2007 Annual Scientific Session, March 26 2007. *Journal of American College of Cardiology* 2007; 49 Supplement A.
89. **Kaul S**, Diamond GA, Shah PK. Drug-Eluting Stents: An Ounce of Prevention for a Pound of Flesh? American College of Cardiology 2007 Annual Scientific Session, March 26 2007. *Journal of American College of Cardiology* 2007; 49 Supplement A.
90. Amin S, Eshaghian S, Shah PK, Diamond, GA, **Kaul S**. Should Clinical Guidelines Emphasize Statistical Significance over Clinical Importance? A Reappraisal of the 2004 ACC/AHA Treatment Guidelines for STEMI. American College of Cardiology 2007 Annual Scientific Session, March 26 2007. *Journal of American College of Cardiology* 2007; 49 Supplement A.
91. Eshaghian S, Amin S, Shah PK, Diamond, GA, **Kaul S**. How Likely Are Therapeutic Interventions Recommended by the 2002 ACC/AHA Clinical Guidelines for Acute Coronary



- Syndromes to be Clinically Worthwhile? American College of Cardiology 2007 Annual Scientific Session, March 26 2007. Journal of American College of Cardiology 2007; 49 Supplement A.
92. **Kaul S**, Diamond GA. Should Bivalirudin be the Preferred Antithrombotic Agent of Choice During Elective or Urgent Percutaneous Coronary Intervention? A Bayesian Analysis of REPLACE-2 and ACUITY Trials. American College of Cardiology 2007 Annual Scientific Session, March 26 2007. Journal of American College of Cardiology 2007; 49 Supplement A.
93. Das JR, Joffe M, Diamond GA, Shah PK, **Kaul S**. To Intervene or Not to Intervene: A Meta-analysis of Early Invasive versus Early Conservative Management for Acute Coronary Syndromes. American College of Cardiology 2007 Annual Scientific Session, March 26 2007. Journal of American College of Cardiology 2007; 49 Supplement A.
94. Das JR, Joffe M, Diamond GA, Shah PK, **Kaul S**. Does Early Invasive Strategy Provide a Clinically Important Advantage Over Early Conservative Strategy in the Management of Acute Coronary Syndromes? American College of Cardiology 2007 Annual Scientific Session, March 26 2007. Journal of American College of Cardiology 2007; 49 Supplement
95. **Kaul S**, Das J, Shah PK, Diamond GA: Percutaneous Coronary Intervention for Management of CAD: Evidence-Based or Enthusiasm-Bound? American Heart Association 2007 Annual Scientific Session, November 6, 2007. Circulation 2007; 116, Supplement II-668
96. Diamond GA, **Kaul S**: *Nessun dorma*. Have the Risks of Rosiglitazone Been Exaggerated? American Heart Association 2007 Annual Scientific Session, November 6, 2007. Circulation 2007; 116, Supplement II.
97. Das J, Diamond GA, Eshaghian S, Amin S, Shah PK, **Kaul S**. The Impact of Homocysteine-Lowering Therapy on Cardiovascular Outcomes: An Updated Meta-analysis of 13 Trials. (Accepted for ACC 2008 Annual Scientific Session).
98. Das J, Amin S, Eshaghian S, Diamond GA, Shah PK, **Kaul S**. Early Invasive Strategy in the Management of Unstable Angina/Non ST-elevation Myocardial Infarction: Predictors of Benefit. (Accepted for ACC 2008 Annual Scientific Session).
99. Das J, Eshaghian S, Amin S, Diamond GA, Shah PK, **Kaul S**. Does Early Invasive Strategy Provide Long-Term Benefit In Management of Unstable Angina/ Non ST-Elevation Myocardial Infarction? (Accepted for ACC 2008 Annual Scientific Session).
100. Eshaghian S, Das J, Amin S, Polk DM, Shah PK, Diamond GA, **Kaul S**. The 2006 AHA/ACC Secondary Prevention Guidelines for Cardiovascular Disease: The Relative Effectiveness of Pharmacologic vs Therapeutic Lifestyle Interventions. (Accepted for ACC 2008 Annual Scientific Session).
101. Das J, Diamond GA, Eshaghian S, Amin S, Shah PK, **Kaul S**. Meta-Analysis of Percutaneous Coronary Intervention versus Medical Therapy for Relief of Angina in Chronic Stable CAD. (Submitted for ACC 2008 Annual Scientific Session).
102. **Kaul S**, Diamond GA, Shah PK. Do High-Risk Characteristics (History of Stroke or TIA, Age >75 years, Weight <60 Kg) Reliably Predict Bleeding in TRITON-TIMI 38? (Accepted for AHA 2008 Annual Scientific Session).
103. **Kaul S**, Shah PK, Diamond GA. Validity of the Combined Efficacy plus Safety Composite Endpoint (Net Clinical Benefit) in TRITON-TIMI 38. (Accepted for AHA 2008 Annual Scientific

Session).

104. **Kaul S**, Shah PK, Diamond GA. Does Prasugrel Provide a Clinically Important Treatment Benefit Compared with Clopidogrel? A Bayesian Analysis of TRITON-TIMI 38. (Accepted for AHA 2008 Annual Scientific Session).
105. **Kaul S**, Shah PK, Diamond GA Timing of Benefit with Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Reanalysis of TRITON-TIMI 38 Results. (Accepted for AHA 2008 Annual Scientific Session).
106. **Kaul S**, Shah PK, Diamond GA Weighted Composite Endpoint Analysis of TRITON-TIMI 38: Disconnect Between Analytical Equivalence and Clinical Importance. (Accepted for AHA 2008 Annual Scientific Session).
107. Eshaghian S, Chou S, Das J, Shah PK, Diamond GA, **Kaul S**. Does the Evidence Support Guideline Recommendations for Clopidogrel Pretreatment? (Accepted for AHA 2008 Annual Scientific Session).
108. Kolm P, Diamond GA, Spertus JA, Maron DJ, Teo KK, O'Rourke RA, Mancini GBJ, Dada M, **Kaul S**, Boden WE, Weintraub WS. A Meta-Analysis of Randomized Trials of Percutaneous Coronary Intervention or Medical Therapy in Stable Coronary Artery Disease vs. Post-Infarction Patients. (Accepted for ACC 2009 Annual Scientific Session).
109. Azarbal B, Shah PK, Diamond GA, **Kaul S**. Will Bivalirudin Outperform Heparin Alone During Primary PCI for STEMI? (Accepted for ACC 2009 Annual Scientific Session).
110. **Kaul S**, Azarbal B, Shah PK, Diamond GA. Bivalirudin versus Heparin Alone in Low-Risk PCI: Indirect vs Direct Comparison. (Accepted for ACC 2009 Annual Scientific Session).
111. DeMaria AN, De Lemos JA, Diamond GA, Greenland P, Gudnason V, Hachamovitch R, Higashi MK, Peskin BP, **Kaul S**. Comparative Efficacy of Strategies for Risk Screening and Prevention for Cardiovascular Disease. (Accepted for ACC 2009 Annual Scientific Session).
112. **Kaul S**, Diamond GA. Non-inferiority lies in the eyes of the beholder: Reassessment of TAXUS ATLAS trial. (Submitted for ACC 2009 Annual Scientific Session).
113. **Kaul S**, Houle FA, Hinsberg WD, Yeghiazarian L, Diamond GA. Less is More: An Optimal Selective Strategy for Use of Drug-Eluting Stents Based on a Kinetic Model of Restenosis and Thrombosis. (Submitted for ACC 2009 Annual Scientific Session).
114. **Kaul S**, Houle FA, Hinsberg WD, Yeghiazarian L, Diamond GA. Effect of Long-Term Anti-Platelet Therapy on Drug-Eluting Stent Thrombosis Based on Kinetic Model Projections. (Submitted for ACC 2009 Annual Scientific Session).
115. **Kaul S**, Azarbal B, Shah PK, Diamond GA Will Bivalirudin Provide Superior Efficacy or Safety versus Heparin Alone During Contemporary Management of Patients with Moderate-to High-risk ACS? Results from an Indirect Comparison. (Submitted for ACC 2009 Annual Scientific Session).